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Drug repositioning has gained attention from both academia and pharmaceutical
companies as an auxiliary process to conventional drug discovery. Chemotherapeutic
agents have notorious adverse effects that drastically reduce the life quality of cancer
patients so drug repositioning is a promising strategy to identify non-cancer drugs which
have anti-cancer activity as well as tolerable adverse effects for human health. There
are various strategies for discovery and validation of repurposed drugs. In this review,
25 repurposed drug candidates are presented as result of different strategies, 15 of
which are already under clinical investigation for treatment of prostate cancer (PCa).
To date, zoledronic acid is the only repurposed, clinically used, and approved non-
cancer drug for PCa. Anti-cancer activities of existing drugs presented in this review
cover diverse and also known mechanisms such as inhibition of mTOR and VEGFR2
signaling, inhibition of PI3K/Akt signaling, COX and selective COX-2 inhibition, NF-κB
inhibition, Wnt/β-Catenin pathway inhibition, DNMT1 inhibition, and GSK-3β inhibition.
In addition to monotherapy option, combination therapy with current anti-cancer drugs
may also increase drug efficacy and reduce adverse effects. Thus, drug repositioning
may become a key approach for drug discovery in terms of time- and cost-efficiency
comparing to conventional drug discovery and development process.
Keywords: prostate cancer, drug repositioning, non-cancer therapeutics, repurposing, approved drugs
INTRODUCTION
The nature presented itself as a potential drug resource for scientists enabling serendipitous
discoveries for centuries. The venture of drug discovery has started with random screening of crude
plants such as reserpine, lavender, and opium, and latterly created the drug industry, which is the
one of the most advanced industries in our society (Giridhar, 2012). As a part of this industry, the
drug discovery process had enormous investments into infrastructures. Research and development
(R&D) require huge amounts of time and money. Further, translation of the promising molecule to
Abbreviations: AR, androgen receptor; CMT, chemically modified tetracycline; CRPC, castration-resistant prostate
cancer; DR, drug repositioning; EMT, epithelial-to-mesenchymal transition; ER, endoplasmic reticulum; HDAC, histone
deacetylases; HMG-CoA, 3-hydroxy-3-methylglutaryl; JHCCL, Johns Hopkins Clinical Compound Library; MMP, matrix
metalloproteinases; NCGC, National Health Institute Chemical Genomics Center; NPC, NCGC pharmaceutical collection;
NSAID, non-steroidal anti-inflammatory drug; PCa, prostate cancer; PSA, prostate-specific antigen; VPA, valproic acid; ZA,
zoledronic acid.
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an approved drug has major problems including high failure rates
and withdrawal risks by reason of safety or efficacy problems
(Shim and Liu, 2014; Würth et al., 2016).
Drug repositioning (DR), which is an auxiliary process to
conventional drug discovery has gained attention from both
academia and pharmaceutical companies. Drug repositioning,
also named “drug repurposing or drug recycling,” is a
promising approach to overcome hurdles in discovering and
developing new drugs via identification of the new therapeutic
applications of known drugs. Repurposed drug candidates have
established formulations and manufacturing methods, extensive
pharmacokinetic properties, known adverse effects, clinical trial
information, and post-marketing surveillance safety data which
make a beeline for the drug development with less chance
of failure (Deotarse et al., 2015). To date, there are many
success stories about repositioned drugs. The first and most
well-known example of DR was discovered serendipitously.
Sildenafil was originally produced to be used in coronary artery
disease but after the failure on phase 2 trials, it was directed
to the treatment of erectile dysfunctions because of its side
effect in inducing penile erections (Li and Jones, 2012; Deotarse
et al., 2015). Thalidomide, everolimus, nelfinavir, minoxidil,
and more drugs have been proven effective in treating another
disease than intended at first indications (Huang et al., 2011;
Li and Jones, 2012; Pantziarka et al., 2014; Deotarse et al.,
2015).
Cancer is one of the most complex diseases as well as
the leading cause of death worldwide. Epidemiologic studies
pointed out 14.1 million new cancer cases and 8.2 million
deaths globally in 2012. Among all cancer types, prostate cancer
(PCa) is the fourth most prevalent cancer without distinction
of gender and the second most prevalent cancer among men.
An approximate 1.1 million cases were diagnosed with PCa in
2012, accounting for 15% of the cancers diagnosed worldwide
in men (Ferlay et al., 2015). A recent report showed that PCa
in the United States is the first and second leading cancer type
considering estimated new cases and deaths, respectively (Siegel
et al., 2018).
Most of the conventional anti-cancer chemotherapeutic
agents may have notorious adverse effects that drastically
reduce the life quality of cancer patients. Therefore, DR is
an encouraging strategy to identify non-cancer drugs having
anti-cancer activity as well as little or tolerable adverse
effects for human health. Hence, DR and any progression
on workflows for efficient DR may ameliorate the professed
inefficiency of conventional drug development process as
previously discussed (Shim and Liu, 2014; Vanhaelen et al.,
2017).
In the context of drug discovery, this review focuses on
non-cancer drugs that are repurposed to be used as potential
PCa therapeutics. We begin by discussing the different DR
approaches which enable the researchers to not only discover new
candidates but also validate their results as a part of the study.
Second, a comprehensive overview is given on the repurposed
non-cancer drugs against PCa which have been under clinical
investigation until now. Finally, we discuss the gaps and future
challenges on drug repositioning approaches and the concepts to
propel the field forward for treating PCa as well as other cancer
types. Drugs repositioned for PCa treatment may potentially be
used in other cancer types since common pathways or targets
might be shared in different cancer types regardless of tissue
types.
DRUG REPOSITIONING APPROACHES
FOR THE TREATMENT OF PCa
Drug repositioning approaches are applicable when discovering
new therapeutics and also validating the candidate drugs. We
evaluated methods used for discovery of new therapeutics in
three main categories (Figure 1) and explained them in terms
of PCa treatment. Activity-based DR and in silico-based DR
were mentioned previously (Shim and Liu, 2014). However,
a notable number of current drug repositioning studies for
PCa were established based on observations from previous
studies. Therefore, we aimed to consolidate this categorization
with knowledge-based DR. We provide examples of DR for
PCa comprising different discovery and validation methods
(Table 1). We also discuss alternative/complementary approaches
and their advantages/disadvantages for new drug discovery
(Table 2).
Knowledge-Based Drug Repositioning
The term “knowledge-based drug repositioning” represents drug
repositioning based on knowledge of the medical doctors or
researchers and their ability to interpret scientific observations
or just coincidences. The first examples of drug repositioning
were found serendipitously while working on another disease.
Afterward, similar disease indications, sharing altered pathways
or the need of combination therapies, led researchers to look
for observations and repurpose drugs for a disease rather
than the originally targeted one. Hence, these success stories
have become prominent and still practicing in the context of
drug repositioning. Recent knowledge-based DR studies on PCa
have presented new candidates such as ormeloxifene (Hafeez
et al., 2017), naftopidil (Iwamoto et al., 2017), ferroquine (FQ)
(Kondratskyi et al., 2017), nelfinavir (Guan et al., 2015),
nitroxoline (Chang et al., 2015), and glipizide (Qi et al.,
2016).
Previous studies showed that loss of E-cadherin accompanying
abundancy of N-cadherin is involved in epithelial-to-
mesenchymal transition (EMT), leading to PCa being metastatic
and more aggressive. Moreover, aberrant expression of β-catenin
which plays a major role in EMT is a part of the major
oncogenic signaling pathways (Jaggi et al., 2005, 2006).
Hafeez et al. (2017) suggested that the clinically approved
selective estrogen receptor modulator, ormeloxifene, may
inhibit EMT by repressing N-cadherin and β-catenin/TCF-4
transcriptional activity. Ormeloxifene has already been reported
to demonstrate anti-cancer activity in different carcinoma
such as ovarian, head and neck, and breast. However, Hafeez
et al. (2017) studied ormeloxifene for the treatment of PCa
and explained its effects on EMT processes and Wnt/β-catenin
signaling. To validate their hypothesis, they used molecular
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FIGURE 1 | Different drug repositioning approaches for drug discovery and validation.
docking as an in silico validation method and ormeloxifene
showed proficient docking with β-catenin and GSK-3β. In
addition, in vitro cell culture studies showed that ormeloxifene
induced apoptosis, and reduced tumorigenic, metastatic,
and invasive potential of PCa cells. Moreover, treatment
remarkably reduced the prostate tumor growth in the
xenograft mouse models as in vivo validation for effects of
ormeloxifene.
Radiotherapy (RT) is an alternative option to surgery
for the treatment of localized PCa. However, cancer cells
develop resistance to RT, since RT induces upregulation of
anti-oxidant enzymes which decompose free radicals inside
the cancer cell and protect them. To increase efficiency
of therapy, RT has been investigated in combination with
Akt inhibitors (Xu et al., 2010) and, in another study,
with a Hedgehog inhibitor (Gonnissen et al., 2016). The
selective adrenoreceptor A1D antagonist naftopidil is used for
treating lower urinary tract symptoms triggered by benign
prostatic hyperplasia (Masumori, 2011). Iwamoto et al. (2017)
proposed naftopidil therapy in combination with RT to increase
treatment efficiency. They reported significant growth inhibitory
effects in addition to Akt phosphorylation-inhibitory effects of
naftopidil.
Targeting autophagy was presented as promising direction
to repurpose anti-cancer therapeutics and therefore discussed
in detail (Piao and Amaravadi, 2016; Rebecca and Amaravadi,
2016), since autophagy is upregulated in many cancers and
promotes survival of cancer cells in particular on advanced
stages that are under metabolic stress. In addition, lysosomes
have a major role in autophagy and effective lysosomal
function plays a critical role in tumor invasion, resistance to
apoptosis and angiogenesis. In addition to two anti-malarial
drugs, chloroquine (CQ) and hydroxychloroquine (HCQ),
which have already been under clinical investigation for
further use in cancer therapy, Kondratskyi et al. (2017)
investigated FQ, another anti-malarial agent. They reported
that FQ effectively inhibits autophagy, agitates lysosomal
functions, and negatively affects tumor growth in vivo.
Results showed that even in extreme conditions such as
starvation and hypoxia observed in advanced solid cancers, FQ
negatively regulates Akt kinase and hypoxia-inducible factor-1α
(HIF-1α).
Nitroxoline is a widely used antibiotic for treating urinary
tract infections due to its pharmacokinetically long retention
time in urine (Zhang et al., 2016). Several target-based and
cell-based assays demonstrated nitroxoline as an anti-cancer
agent leading to the inhibition of endothelial cell proliferation
for different cancer types including lymphoma, leukemia,
pancreatic cancer, ovarian cancer (Jiang et al., 2012), bladder
cancer (Shim et al., 2010), and breast cancer (Sosiè et al.,
2013). Furthermore, nitroxoline could potentially be useful for
therapeutic development against PCa, since the drug results in
AMPK-dependent inhibition of the mTOR signaling pathway
and cyclin D1-Rb-Cdc25A axis, leading to apoptosis (Chang
et al., 2015).
Nelfinavir is a FDA-approved human immunodeficiency virus
(HIV) protease inhibitor which was used in combination therapy
for HIV infected patients. Nelfinavir has also been reported to
exhibit distinct anti-cancer mechanisms such as endoplasmic
reticulum (ER) stress-unfolded protein response pathway
and Akt inhibition in various carcinomas such as ovarian,
pancreatic, and breast (Koltai, 2015; Bhattarai et al., 2016)
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TABLE 1 | Non-cancer drug repositioning candidates for prostate cancer and their repurposing strategies.
Drugs Original Use Proposed Anti-cancer Mechanisms Repurposing Methods Validation Methods Reference
Naftopidil Alfa-blocker -Akt phosphorylation inhibitory effects
-Inhibiting prostate tumor growth
Knowledge-based In vitro In vivo Iwamoto et al., 2017
Niclosamide Anti-helminthic agent -Inducing Wnt co-receptor LRP6
degradation
-Inhibiting the Wnt/β-Catenin Pathway
Knowledge-based In vitro Lu et al., 2011
Ormeloxifene Estrogen Receptor
Modulator
-Inhibition of oncogenic β-catenin
signaling and EMT progression
-Suppresses prostate tumor growth
and metastatic phenotypes
Knowledge-based In silico In vitro In vivo Hafeez et al., 2017
Nelfinavir Anti-retroviral agent -Inhibiting proliferation and inducing
apoptosis
-Suppression of regulated membrane
proteolysis
Knowledge-based In silico In vitro Guan et al., 2015
Glipizide Anti-diabetic agent -Inhibiting angiogenesis Knowledge-based In vivo Qi et al., 2016
Ferroquine Anti-malarial agent -Inhibiting autophagy
-Negatively regulation of Akt kinase and
HIF-1α
Knowledge-based In vitro In vivo Kondratskyi et al., 2017
Nitroxoline Anti-bacterial agent -Induced G1 arrest of cell cycle and
subsequent apoptosis
-Induced autophagy through an
AMPK-dependent pathway
Knowledge-based In vitro Chang et al., 2015
Triclosan Anti-bacterial agent -Inhibition of FASN
-TCS binds and inactivates the enoyl
reductase domain
Activity-based In vitro Sadowski et al., 2014
Digoxin Anti-arrhythmic agent -Causing an influx of intracellular
calcium into prostate cancer cells
-Triggering apoptosis
-Potential HIF-1α inhibitor
Activity-based In silico Platz et al., 2011
Clofoctol Anti-bacterial agent -Activation of unfolded protein
response pathways
-Induction of G1 cell cycle arrest in
prostate cancer cells
Activity-based In vitro In vivo Wang et al., 2014
Risperidone Anti-psychotic agent -Inhibition of 17HSD10 which is an
intracellular binding partner for Amyloid
b-Peptide and overexpressed in PCa
bone metastasis
In silico In silico In vitro In vivo Dilly et al., 2017
Dexamethasone Anti-inflammatory agent -Modulator of ERG activity In silico In silico In vitro Gayvert et al., 2016
Zenarestat Aldose reductase
inhibitor
-Potent inhibitor of NF-κB pathway In silico – Turanli et al., 2017
TABLE 2 | Different approaches for drug repositioning.
Approaches Advantages Disadvantages
Knowledge-based DR Mainly based on researchers’ know-how Higher rate of false positive related to the observations
Time- and cost-efficient process Limited number of drugs evaluated at once
Easy to validate in pre-clinical and clinical studies
Activity-based DR Lower rate of false positive hits during the experiments Requires an entire collection of drugs
Easy to validate in pre-clinical and clinical studies Time-consuming and costly process
No limitation for target-based and cell-based screening assays Requires developing an assay for pre-screening
In silico DR Time- and cost-efficient process Higher rate of false positive hits during the experiments
No need an entire collection of existing drugs Highly dependent on availability of information such as structural
information of target proteins, disease phenotype information, etc.
Easy to integrate different methods Low accuracy of predicting new drug-target interactions
Easy to evaluate huge number of drugs at once
in addition to PCa (Guan et al., 2015). However, even though
nelfinavir has been investigated in phase 1/2 clinical trials
for solid tumors, Kaposi’s sarcoma and others, it is yet to
be evaluated for PCa in clinical trials. The mechanisms
of action for anti-tumor properties of nelfinavir appear
numerous including inhibition of (PI3K)/Akt signaling pathway,
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the proteasome and HIF-1α which inhibits angiogenesis, and
induction of ER stress, autophagy, and apoptosis (Gantt et al.,
2013).
Activity-Based Drug Repositioning
The need of repurposed drugs is increased to compensate the low
success rate of conventional or de novo drug discovery processes.
On the other hand, the availability of established drug libraries
led researchers to create more rational designs compared to
knowledge-based drug repositioning. The term “activity-based
drug repositioning” stands for testing actual drugs in assays.
To date, besides the ones provided by commercial companies,
there are two publicly available comprehensive clinical
compound libraries, established through support of government
and private agencies (Padhy and Gupta, 2011). The first
initiative, Johns Hopkins Clinical Compound Library (JHCCL),
was launched in early 2000s as a joint collaboration between
Johns Hopkins Pharmacology and Johns Hopkins Bloomberg
School of Public Health. JHCCL is the largest publicly accessible
collection of existing drugs with approximately 3,100 available
compounds, many of which are FDA-approved or approved by
its foreign counterparts (Padhy and Gupta, 2011; Shim and Liu,
2014). Second collection was built by NIH Chemical Genomics
Center (NCGC) and called NCGC Pharmaceutical Collection
(NPC) which possess 2,500 small compounds that have been
approved for clinical use by the United States (FDA), European
(EMA), Japanese (NHI), and Canadian (HC) authorities (Huang
et al., 2011). NPC is also comprehensive, publicly accessible
collection of approved compounds along with approximately
1,000 additional investigational compounds for high-throughput
screening. There are also commercially available clinical drug
collections on the market. These drug collections have been
recognized as valuable resources for DR purposes in many
academic studies. To get a comprehensive drug library, the
compounds (i.e., off-patent drugs) that are easy to obtain in
terms of price and patent restrictions are generally collected
first. Drugs with patent that covers drug synthesis or use will
be the most difficult and expensive to obtain, concerning price
per compound. Major drug metabolites should be included into
collections to increase the size of the drug library, as most of them
often have diverse pharmacological properties. For instance,
fexofenadine, which is a non-sedating anti-histamine, lacks the
cardiotoxic side effects of its parent terfenadine (Sussman et al.,
1999). These comprehensive drug libraries can be used for both
protein target-based and cell-based screens which shed a light on
clinical trials (Shim and Liu, 2014).
Despite the great potential of the activity-based DR, even
the largest publicly available drug collection, JHCCL, covers
almost 30% of roughly 10,000 drugs in clinic. Though this
seems a large library, it pales in comparison with the libraries
of novel compounds (100,000 or more) held by pharmaceutical
companies. Availability is another issue for drug screening.
JHCCL shared the drug collection with over 45 researchers
worldwide for drug screening against different diseases. This
existing library is publicly and freely available in principle
but requires financing of the replacement of drug stocks and
shipping costs (Chong and Sullivan, 2007). In general, drug
libraries are provided in 384-well plates and can easily be
scaled up. However, unlike the other DR methods, activity-based
DR requires specialized robotics to screen thousands of wells
containing drugs/compounds.
There are several promising hits identified by activity-based
DR including cancers, diabetes, and infectious diseases (Chong
et al., 2006a,b, 2007; McMahon et al., 2007; Zhang et al., 2008;
Kim et al., 2010; Shim et al., 2010; Lin et al., 2011; Platz
et al., 2011). Among the hits, anti-fungal agent, itraconazole,
and cardiac glycoside, digoxin are promising anti-cancer agents
that have been explored through activity-based DR using JHCCL
(Chong et al., 2007; Zhang et al., 2008). To date, phase 2
clinical studies evaluating the anti-tumor efficacy of itraconazole
were completed for treatment of metastatic non-squamous non-
small cell lung cancer (Rudin et al., 2013) and metastatic PCa
(Antonarakis et al., 2013). Digoxin was found to have significant
effect both at the epidemiological and experimental levels (Platz
et al., 2011) and clinically trialed in PCa cases (Lin et al., 2014).
Triclosan [5-chloro-2-(2,4-dichlorophenoxy) phenol] is
effective against many different bacteria as well as some fungi
and protozoa. It has been widely used as a broad-spectrum anti-
bacterial and anti-fungal agent for more than 30 years. It is found
in formulations as diverse as cosmetics, fabrics, toothpastes,
plastic kitchenware, and toys. In previous studies, triclosan
demonstrated blocking effect on lipid synthesis (McMurry et al.,
1998; Levy et al., 1999). Deregulated lipid metabolism and FASN
inhibition has emerged as a promising therapeutic target in
cancer patients. Sadowski et al. (2014) inhibited FASN and
compared the cellular and molecular effects of triclosan in both
malignant and non-malignant prostate cells compared to the
other well-known FASN inhibitors C75 and orlistat. As a result,
they proposed triclosan as a promising drug candidate against
PCa with a superior cytotoxic profile in comparison with C75 or
orlistat.
Clofoctol is an antibiotic used in the therapy of upper
respiratory tract infections. It was previously reported to inhibit
protein translation in mammalian cells and it is a potential
anti-cancer drug (Pelletier et al., 2007). Wang et al. (2014)
demonstrated a quite unique mechanism of action of clofoctol
that inhibits prostate tumor growth as well as protein translation
in PCa cells. It has indirect effect via inducing ER stress and
activating unfolded protein response pathways which serve a
cellular protective mechanism to cope with an excess of misfolded
proteins in the ER.
In Silico Drug Repositioning
In silico drug repositioning is a potentially powerful strategy since
data acquired from structural biology and omics technologies
have been accumulating in the past few decades. In silico DR
provides a faster repurposing process as well as reduced costs
through different approaches such as molecular docking, network
analysis, data mining, similarity analysis, machine learning, and
transcriptional signatures (Figure 1). Different methods covered
by in silico DR has been recently reviewed in detail (Vanhaelen
et al., 2017).
In recent years, in silico DR methods have been focused
on identification of candidate targets and potential drugs
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considering data from different omics levels as well as the
disease-gene-drug triad (Sun et al., 2017). Publicly available
clinical data at genomic and/or transcriptomic levels were
evaluated within a comprehensive, systematic, and integrative
analysis pipelines in several studies to find out new drug
candidates for particular medical problem (Sirota et al., 2011;
Jin et al., 2012; Turanli et al., 2017). Computational predictions
supported by experimental assessments have been effectively
used to determine new DR potentials. In contrast, powerful
computational resources such as software for retrospective
analysis or structural biology and maintenance of web-based
databases are decisive for the collection and evaluation of the
experimental data (Vanhaelen et al., 2017).
Risperidone, a benzisoxazole derivative, is an anti-psychotic
agent which has proven efficacy in the treatment of most common
central nervous system disorders such as depression, bipolar
disorder, and schizophrenia (Roth et al., 2004). Although the
drug mechanism is not clear, it has been reported that it has
a high binding affinity for both dopamine D2 and serotonin
5-HT2 receptors (Abou El-Magd et al., 2010). Another molecular
target of risperidone, 17-b-hydroxysteroid dehydrogenase 10
(17HSD10), plays a significant role as an intracellular binding
partner for amyloid β-peptide which is important in Alzheimer’s
disease. Additionally, it is suggested for treatment of PCa
to stimulate dihydrotestosterone synthesis in the absence of
testosterone and also highly expressed in PCa bone metastases
(Ayan et al., 2012). Recently, Dilly et al. (2017) reported
risperidone as a DR candidate targeting 17HSD10. They
combined both activity-based and in silico DR methods through
the discovery process, and then tested other similar drugs in
addition to risperidone in silico, in vitro and in vivo through
validation process.
Acetic acid derivative, zenarestat is an aldose reductase
inhibitor originally used for preventing diabetic cataractogenesis,
retinopathy, and neuropathy (Schemmel et al., 2010; Zhu, 2013).
Since aldose reductases activate the transcription of NF-κB and
AP-1 which transcribe the genes of inflammatory cytokines
and oxidative stress-induced inflammation which promotes the
formation of cancerous tumors, recent investigations strongly
suggest that the use of aldose reductase inhibitors can be
novel chemotherapeutic agents against cancer (Tammali et al.,
2011). As an in silico DR application, the web-based DR tool,
geneXpharma, has taken into consideration comprehensive gene
expression profiling and the disease-gene-drug association data
and repurposed zenarestat as a candidate drug to be used in PCa
treatment at the point of experimental validation (Turanli et al.,
2017).
As always, every computational approach has its own
advantages and limits based on the problem to be solved and
on the type, quality, and quantity of information available
about the problem in the literature or in public/commercial
databases. As an example, molecular docking requires high
resolution structural information of drugs and targets (Shim
and Liu, 2014). The integration of different computational
methods and information coming from different sources such as
biological, structural, and clinical databases could serve valuable
opportunities in the manner of purposing new use of an old
drug (March-Vila et al., 2017). However, none of these methods
are sufficient enough to model the complex interactions among
drugs, targets and diseases. Keeping this in mind, in silico drug
repositioning could represent a primary method in order to
highlight novel small molecules or drug compounds through
initiating with a hypothesis or generating new hypotheses about
how these compounds work and what their primary targets
are and eventually, such hypotheses may drive the systematic
design of downstream experiments. Although there are plenty
of computational methods, their integration can surpass the
methods applied alone.
After brief explanations of each perspective, it sounds that
any of them has their own pros and cons as summarized in
Table 2. Knowledge-based DR is solely dependent on researches’
knowledge and ability to interpret the scientific observations
or just coincidences. It is not only a time- and cost-efficient
process, but also easy to validate in pre-clinical and clinical
studies if observations were experimentally investigated. On the
other hand, it is not the systematic way comparing to the other
DR methods, and therefore it may appear risky. In silico systems
has reduced time and cost, however, it always hinges on the
availability of the experimental data such as structure or gene
expression profiles at first. The biological significance of the
putative targets predicted by the computationally method must
also be experimentally assessed. On the other hand, activity-
based DR is time- and labor-consuming; requiring an entire
collection of existing drugs, specialized equipment and develop
a screening assay, but it can be employed without requiring
structural information of target proteins or database. Moreover,
activity-based DR is easy to validate since it experiences low false
positive rates with regard to in silico repositioning (Shim and Liu,
2014).
REPURPOSED AND CLINICALLY
EVALUATED NON-CANCER DRUGS FOR
PCa TREATMENT
We briefly summarize the non-cancer approved drugs which
are repurposing for PCa treatment via different DR approaches
in Table 1. Moreover, chemical structures of all potential non-
cancer drugs against PCa were shown in Figure 2. Here, we
provide an overview only on existing drugs with anti-PCa
activities that are under clinical investigation as reviewed in
Table 3.
Dexamethasone
Dexamethasone is one of the glucocorticoids that prevent
inflammation and has immunosuppressive activity. It serves
potential to treat several different diseases such as allergic
disorders, inflammatory disorders (ulcerative colitis, arthritis,
lupus, psoriasis), or breathing disorders (Buttgereit et al., 2011).
Dexamethasone in combination with other chemotherapeutic
drugs is used to counteract certain side effects of chemotherapy
such as edema, emesis, etc. For instance, it is used to stabilize the
development of edema in brain tumors, which could eventually
compress other brain structures or spinal cords (Chu et al., 2014).
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FIGURE 2 | Chemical structures of repurposed non-cancer drug candidates for prostate cancer.
The antiemetic action of dexamethasone reduces pain and the
concomitant use of opioids, which in turn reduces opioid-related
nausea and vomiting (Chu et al., 2014). Besides, dexamethasone
can be used alone as a direct chemotherapeutic agent in
certain hematological malignancies, especially in the treatment of
multiple myeloma (Bhattarai et al., 2016). Although combination
of dexamethasone with chemotherapeutic agents were already
clinically tested in PCa patients (Shamash et al., 2011), oncogenic
transcription factors were also targeted via systematic drug-
transcription factor. Analysis predicts the candidate small
molecules in one recent in silico DR study, and they showed the
effect of dexamethasone on prostate tumor by inhibiting ERG
Activity (Gayvert et al., 2016).
Aspirin
Acetylsalicylic acid or aspirin is used as an analgesic and
non-steroidal anti-inflammatory drug (NSAID) in a variety of
conditions ranging from headache, fever associated with the
common cold, pain in rheumatoid arthritis and other similar
musculoskeletal conditions (Kar, 2007).
It is known as a cyclo-oxygenase enzyme (COX-1 and 2)
inhibitor with a great affinity (Yoshimura et al., 2000). To date,
the NSAIDs such as aspirin, which inhibits both COX-dependent
and/or independent pathways has been speculated to be used
against some malignancies including colorectal, esophageal
cancer, breast as well as prostate (Downer et al., 2017).
Particularly, COX-2 which plays role in carcinogenesis,
angiogenesis, poorer prognosis in PCa (Liu et al., 2014), and
inhibition of immune surveillance (Kirschenbaum et al., 2001)
is highly expressed in malignant prostate tissue compared
to benign human prostate tissue. Anti-cancer mechanism of
aspirin is the inhibition of COX-2 which leads to suppression
of the neoplastic prostaglandins production. In addition to its
classical role as COX inhibitor, it suppresses activation of NF-κB
induced by TNF, upregulation of tumor suppressor gene, and
downregulation of anti-apoptotic gene (Bhattarai et al., 2016).
To date, several epidemiologic studies and meta-analyses of
prospective and case-control cohort studies have discussed the
use of NSAID as well as aspirin in PCa cases worldwide and
reviewed in detail (Fowke et al., 2009; Mahmud et al., 2010;
Liu et al., 2014; Vidal et al., 2015; Bilani et al., 2017). However,
results were inconsistent since some studies suggested a reduced
risk of total PCa and PCa-specific mortality in association with
NSAID use, some reported no benefit or elevated risk of PCa
(Assayag et al., 2015). Liu et al. (2014) indicated the effect of any
NSAID on PCa varied by geographic region. North American
studies reported a decreased risk of PCa (Vidal et al., 2015),
whereas studies from Europe found elevated risk due to the use of
any NSAID. Potent effect of aspirin for PCa detection were also
addressed in the context of PCa prevention (Fowke et al., 2009).
Diclofenac
Diclofenac is another anti-inflammatory and analgesic from
the NSAID family and it functions as an inhibitor of COX-
2 and prostaglandin E2 synthesis like aspirin. Combination or
monotherapies of diclofenac have been reported to have positive
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TABLE 3 | Non-cancer drug repositioning candidates under clinical investigation for the treatment of prostate cancer.
Drugs Original Use Proposed Anti-cancer Mechanisms Phase Identifier∗ Recruitment Status
Zoledronic Acid Bisphosphonate Inhibition of mevalonate pathway Activity of
metalloproteinases
Phase 4 NCT00219271 Completed
Dexamethasone Anti-inflammatory agent Modulator of ERG activity Phase 3 NCT00316927 Completed
Aspirin Anti-inflammatory agent COX inhibitor suppression of the neoplastic
prostaglandins Inhibition of NF-κB
Phase 3 NCT00316927 Completed
Minocycline Anti-bacterial agent Inhibition of pro-inflammatory cytokines
Inhibition of matrix metalloproteinases
Phase 3 NCT02928692 Recruiting
Celecoxib Anti-inflammatory agent Selective Cox-2 inhibitor Inhibition of NF-κB
activity Inhibition of PDPK1/Akt signaling
pathway
Phase 2/3 NCT00136487 Completed
Leflunomide Immunomodulatory agent Potent inhibitor of tyrosine kinases Phase 2/3 NCT00004071 Completed
Statins HMG-CoA reductase inhibitors Inhibition of mevalonate pathway Phase 2 NCT01992042 Completed
Metformin Anti-diabetic agent PI3K/Akt/mTOR signaling pathway Triggering
apoptosis Inhibition of hepatic gluconeogenesis
Phase 2 NCT03137186 Recruiting
Valproic acid Anti-epileptic agent Histone deacetylases inhibitor Inhibition of
SMAD4 expression
Phase 2 NCT00670046 Unknown
Diclofenac Anti-inflammatory agent Inhibition of COX-2 and prostaglandin E2
Inhibition of MYC
Phase 2 NCT01939743 Completed
Niclosamide Anti-helminthic agent Targeting multiple signaling pathways (NF-κB,
Wnt/β-catenin, Notch, ROS, mTORC1, and
Stat3)
Phase 2 NCT02807805 Recruiting
Itraconazole Anti-fungal agent Anti-angiogenic Hedgehog pathway inhibition
Autophagy induction
Phase 2 NCT00887458 Completed
Digoxin Anti-arrhythmic agent Inhibit HIF-1α synthesis Inhibition of
TNF-α/NF-κB pathway Activation of Src kinase
pathway
Phase 2 NCT01162135 Completed
Mifepristone Anti-progestational agent blocking cell surface receptors on solid tumors Phase 2 NCT00140478 Completed
Disulfiram Alcohol deterrent agent DNMT1 inhibitor Induction of metallothionein
expression
Phase 1 NCT02963051 Recruiting
∗ Identifiers were sourced by https://clinicaltrials.gov.
effects on treating multi cancer types including ovarian cancer,
colorectal cancer, neuroblastoma, and melanoma (Pantziarka
et al., 2016).
High expression of MYC is characterized in many human
malignancies and it leads to the upregulation of glycolytic
enzymes such as glucose transporter-1 (GLUT1) and lactate
dehydrogenase-A (LDHA) resulting high rates of glucose uptake
and glycolysis. Therefore, MYC is a promising target for
cancer therapy. COX-independent effect of diclofenac has been
proposed that it represses MYC and regulates glucose metabolism
via significantly decreased GLUT1 and LDHA gene expression
in melanoma, PCa, leukemia cell line proliferation in vitro, and
reduced melanoma growth in vivo (Gottfried et al., 2013). As
a conventional COX inhibitor, diclofenac augmented the effect
of RT on PCa and proposed as a potential radiosensitizer for
treatment of PCa according to in vitro and in vivo outcomes
(Inoue et al., 2013).
Celecoxib
Celecoxib is another anti-inflammatory drug used for the
treatment of adult arthritis and unlike aspirin and diclofenac,
it is a selective COX-2 inhibitor (Davies et al., 2000). Since
COX-2 is expressed in the malignant epithelial cells as well
as the tumor-feeding neovasculature, celecoxib is a promising
candidate for treating cancer. Additionally, long-term use of
NSAIDs inhibiting both COX-1 and COX-2 have been known to
inhibit the production of COX-1-derived prostaglandins required
for preservation of gut, kidney, and platelet functions (Leahy
et al., 2002). Celecoxib have been reported not only in the
treatment of human epithelial tumor types, such as colorectal,
breast, and non-small cell lung cancers as well as prostate (Elder
et al., 2000; Harris et al., 2000; Hsu et al., 2000), but also in the
prevention of colorectal cancer in high-risk patients with familial
adenomatous polyposis linked to the APC oncogene mutation
(Ponder, 1997).
The main anti-cancer mechanism of celecoxib is to decrease
prostaglandin production in the COX-2 expressed tumors,
resulting in an inhibition of the proliferation and induction
of apoptosis. Moreover, anti-cancer mechanism of celecoxib
via COX-2-independent pathway has been reported such as
inhibition of PDPK1/Akt signaling pathway, inhibition of NF-κB
activity, alteration of APC/β-catenin pathway, and mitochondrial
apoptosis pathway (Kulp et al., 2004; Patel et al., 2005; Grösch
et al., 2006).
The effect of celecoxib on the expression of anti-apoptotic
protein Bcl-2 as well as anti-apoptotic kinase Akt were examined.
Results demonstrated inhibition of Akt activation and induced
apoptosis independent from Bcl-2 via LNCaP and PC-3 cells
in vitro (Hsu et al., 2000). Celecoxib and its analog that does not
inhibit COX-2 were investigated in PC-3 and DU-145 in vitro and
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PC-3 tumor xenograft in vivo resulting inhibition of PDPK1/Akt
signaling pathway (Kulp et al., 2004). Findings from in vivo
and in vitro studies suggested that celecoxib has significant
COX-2-independent anti-tumor properties which makes it active
even in tumors that do not express significant amounts of COX-2.
PCa cell growth was inhibited by inducing a G1 cell cycle
block and reducing DNA synthesis (Patel et al., 2005). Recently,
celecoxib and zoledronic acid were considered complementary
targeting clinically later-stage disease (Mason et al., 2017).
Minocycline
Minocycline is a semi-synthetic tetracycline derivative that
maintains the efficacy against both Gram-positive and
Gram-negative bacteria. It has been approved by FDA,
more than 30 years ago, for the treatment of acne and some
sexually transmitted diseases. Subsequently, experimental
models revealed non-antibiotic properties of minocycline and
determined minocycline beneficial against various disorders
with an inflammatory basis such as dermatitis, periodontitis,
atherosclerosis, and autoimmune diseases such as rheumatoid
arthritis, inflammatory bowel disease (Garrido-Mesa et al., 2013).
Minocycline inhibits the action of proinflammatory cytokines
and matrix metalloproteinases (MMPs) which are extracellular
matrix-degrading enzymes implicated in cancer invasion and
metastasis. Up until now, the drug presents anti-cancer activities
against various cancer cell lines, such as ovarian cancer, glioma,
PCa, melanoma, and breast cancers (Lokeshwar, 2011; Ataie-
Kachoie et al., 2013; Garrido-Mesa et al., 2013). Moreover,
minocycline has been in phase 2 of clinical trials for different
carcinomas such as myeloma, esophageal, pancreatic, colorectal,
lung, head, and neck cancers (Bhattarai et al., 2016) whereas in
phase 3 of clinical trials for PCa.
Lokeshwar (2011) investigated doxycycline, minocycline, and
chemically modified tetracycline (CMT) analogs for treatment of
PCa. Some of these CMTs, notably, CMT-3 and CMT-308, were
found significantly more potent than doxycycline or minocycline
in inhibiting tumor cell-derived MMPs and inducing apoptosis
in vitro and in vivo. In another study, pharmacokinetic
interactions for minocycline with retinoic acid metabolism were
investigated in various PCa cell lines (Regen et al., 2014).
Niclosamide
Niclosamide, the salicyclamide derivative, is an oral
anti-helminthic drug to treat tapeworm infections. In addition
to be used as an anti-infective agent afterward, it has been
demonstrated to exhibit anti-cancer activity in several cancers
such as colorectal cancer (Sack et al., 2011), ovarian cancer (Yo
et al., 2012), acute myeloid leukemia (AML) (Jin et al., 2012), and
breast cancer (Wang et al., 2013). Niclosamide targets multiple
signaling pathways which are closely involved with oncogenesis
and oncoprogression such as NF-κB, Wnt/β-catenin, Notch, and
mTORC1 (Pan et al., 2012).
Niclosamide targets the Wnt co-receptor LRP6 on the cell
surface and that it is potent molecule as a Wnt/β-catenin
signaling and anti-cancer agent for human prostate and breast
cancer due to in vitro studies (Lu et al., 2011). Androgen receptor
(AR) variants that drives resistance to chemotherapeutics such
as enzalutamide are another problem that faced through PCa
treatment. Therefore, niclosamide was evaluated as potential
inhibitor of variant alternatively spliced AR (AR-V7) and
preclinical validation proved that it is promising to treat, either
alone or in combination with current anti-androgen therapies in
advanced PCa patients (Liu et al., 2014).
Itraconazole
Itraconazole was a common triazole anti-fungal agent and
used to inhibit the cytochrome P450-dependent lanosterol
14α demethylase (14DM). The drug causes the destruction of
the fungal membrane and reduction of ergosterol synthesis.
However, the anti-fungal effect of itraconazole is unlikely to be
associated with its potential anti-cancer activities. It can reverse
chemoresistance mediated by P-glycoprotein, adjust the signal
transduction pathways of Hedgehog and Wnt/β-catenin and
inhibit angiogenesis (Kim et al., 2010; Tsubamoto et al., 2017).
The benefits of itraconazole monotherapy for PCa and basal cell
carcinoma were proposed in clinical trials as well as in vitro
studies. Besides, combination of itraconazole and chemotherapy
showed the better survival rates in various cancer types such
as pancreatic, ovarian, and triple negative breast via reducing
endothelial cell proliferation and migration (Chong et al., 2007;
Aftab et al., 2011; Tsubamoto et al., 2017). Several possible
multi-drug combinations have been outlined and are waiting for
clinical trials whereas some of these are on-going. Itracanozole is
addressed as promising drug candidate for rapid implementation
of clinical trials in rare cancers including medulloblastoma, or
certain types of sarcomas (rhabdomyosarcoma, chondrosarcoma,
and osteosarcoma) in which the Hedgehog pathway has an
important role (Pantziarka et al., 2015).
Xu et al. (2010) suggested that itraconazole inhibits the mTOR
and VEGFR2 signaling pathways in endothelial cells by damaging
cholesterol trafficking. Afterward, phase 2 study evaluating the
anti-tumor efficacy of oral itraconazole in men were completed
for treatment of metastatic CRPC. They suggested that high-dose
itraconazole (600 mg/day) might have modest anti-cancer activity
associated with Hedgehog pathway suppression (Antonarakis
et al., 2013).
Digoxin
Digoxin, as a cardiac glycoside, has basically steroid-like structure
including an unsaturated lactone ring and sugar moieties. It
affects cardiac contractility through highly specific inhibition
of the Na+/K+-ATPase pump. Anti-cancer activity of digoxin
may include intracellular decreased level of K+ and increased
level of Na+ and Ca2+ and also inhibits DNA topoisomerase
II, IL-8 production, HIF-1α synthesis, and the TNF-α/NF-κB
pathway and activate the Src kinase pathway (Slingerland et al.,
2013; Calderón-Montaño et al., 2014). Digoxin and its derivatives
have been investigated via preclinical studies in several cancer
types comprising lung, pancreatic, melanoma, leukemia, renal
carcinoma, and the most revised indications were on breast and
PCa (Bhattarai et al., 2016).
After an activity-based DR study in which JHCCL was used,
20 drugs were highlighted whereas 2 of them were known HIF-1
inhibitors (rapamycin and roteone) and 11 of these 20 drugs were
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cardiac glycosides including digoxin, digitoxin, ouabain, etc. As a
finding of this study, digoxin treatment increased latency and
decreased tumor growth in mice. Digoxin was first reported as
an inhibitor of HIF-1α protein and HIF-1 targets such as VEGF,
GLUT1, HK1, and HK2 for PCa (Zhang et al., 2008). On the
contrary, Lopez-Lazaro (2009) argued that neither digoxin has
any inhibitory effect on HIF-1 at therapeutic concentrations, nor
the anti-cancer effects observed in mice are relevant in humans.
As a result of in vitro drug screening using the same drug library,
digoxin has emerged again with inhibitory effect on PCa. As a
following study, evaluation of a large-scale cohort study with
male patients who had heart diseases and took digoxin over
5 years were indicated significantly reduced incidence among
PCa patients who have used it compared with the control group
(Platz et al., 2011).
Valproic Acid
The short chain fatty acid, valproic acid (VPA), is an inhibitor
of class I histone deacetylases (HDAC) used to treat epilepsy,
bipolar disorders, migraine, and schizophrenia. Approximately
20 years ago, the first clinical trial discussing VPA was initiated
and then, several clinical trials for different leukemia, and
solid tumor entities were followed. In addition to clinical
assessments, VPA is still under experimental investigation
regarding the numerous mechanisms of anti-cancer activity
such as inhibition of tumor-associated inflammation, cancer
cell proliferation, tumor angiogenesis, and cancer cell invasion
and migration resulting with metastasis and lastly, inhibition of
histone deacetylases which plays a central role. Since DNA-region
of key anti-cancer genes are tightly bound via histone deacetylase,
VPA, as a HDAC inhibitor, allocates silenced genes to be initiated
(Michaelis et al., 2007).
Acute and chronic administration of VPA were investigated
for PCa cells irrelevant to their androgen sensitivity and also
in vivo tumor xenograft models. Acute treatment increased net
histone H3 acetylation and resulted with upregulated expression
of p21, AR, and cytosolic prostate-specific antigen (PSA) where
the effects on AR and PSA were reversed for chronically
administered VPA in which the cancer cell proliferation rate
was decreased due to increased caspase-2/caspase-3 activation
and also demonstrated statistically significant reduction of tumor
xenograft growth in vivo (Xia et al., 2006). In phase 2 trial to treat
patients with castration-resistant PCa (CRPC), oral VPA was
used with biomarker assessment strategy to study relationship
among PSA, serum testosterone, VPA blood levels, and histone
acetylation. They exerted toxicities regarding oral use of VPA in
the treatment of CRPC patients (Sharma et al., 2008). Lee and
Kim (2015) exerted that VPA is more effective on cell viability and
invasion in metastatic prostate cell line (PC-3) by upregulating
the metastasis suppressor protein NDRG1. VPA is used for the
monotherapy of some cancers such as metastatic neuroendocrine
carcinomas and myeloid malignancies, however, the most of
potent anti-cancer activity of VPA is based on combination
with other epigenetic modifiers (azacytidine, hydralazine),
combinations with cytotoxic chemotherapy agents (5-FU,
epirubicin, cyclophosphamide, doxorubicin, karenitecin), and
combinations with immune-modulators (Brodie and Brandes,
2014). In another study, VPA inhibited the expression of SMAD4
which plays an important role in cancer metastasis via EMT
along with upregulated the expression of miR-34a in prostate
carcinoma (Xia et al., 2016). Very recently, the combination
of metformin and VPA were reported to induce synergistic
apoptosis in the presence of p53 and androgen signaling;
inhibited proliferation of LNCaP and PC-3 cell lines and killed
more PCa cells than either drug alone (Tran et al., 2017).
Statins
Statins are lipid-lowering agents that act by inhibiting
3-hydroxy-3-methylglutaryl (HMG-CoA) reductase resulting
with inhibition of the mevalonate pathway. Statins reduce
cholesterol levels and are mainly used for the treatment
of hypercholesterolemia as well as atherosclerotic plaques
causing cardiovascular problems, such as myocardial infarction,
stroke, and atrial fibrillation (Hindler, 2006). The emerging
interests in the use of statins as anti-neoplastic agents are
based on both in vitro and in vivo studies demonstrating
anti-proliferative, anti-metastatic, RT-sensitizing, and apoptosis
inducing properties (Chan et al., 2003). Preclinical evidences
show that statins inhibit tumor growth and induce apoptosis
in melanoma, glioma, neuroblastoma, and leukemia cell lines
whereas there are numerous clinical trials that have considered
anti-cancer activity of statins in various cancer types such as liver,
gastric, acute myeloid leukemia, and squamous cell carcinoma of
the cervix and of the head and neck (Chan et al., 2003; Hindler,
2006).
Statin use for the treatment of PCa has been associated with
decreased risk of PCa, better prognosis, reduced volume of PCa
and PSA levels, along with its protective effect against PCa
regarding a retrospective cohort study of men who underwent
prostate biopsy (Tan et al., 2011). Numerous studies were in
harmony about the lowering PSA effect of statins. Since increased
levels of PSA are a common symptom guiding biopsy, reduced
PSA levels of statin users were debated in manner of PCa
detection in men. Tan et al. (2011) reported no differences on
PSA levels of PCa diagnosed patients regardless of statin use and
suggested that statin reduces PSA in benign tissue but not in
malignant tissues. Additionally, some studies have demonstrated
a beneficial effect of statins in reducing PCa related mortality as
well as overall PCa risk (Katz et al., 2010; Marcella et al., 2012)
whereas other studies have not revealed a significant effect (Caon
et al., 2014). Recently, conflicting data sourced from clinical
outcomes obstruct the integration of neither beneficial nor
harmful associations between the statin use and PCa (Hutchinson
and Marignol, 2017).
Mifepristone
Mifepristone (RU-486), a steroid synthesized in the laboratory,
is the first anti-progesterone drug with high affinity for the
progesterone receptor (PR) and used for termination of early
pregnancies. Since progesterone is crucial for the initiation and
maintenance of pregnancy, PR also plays an important role in the
human reproductive system (Hazra and Pore, 2001).
Due to knowledge of the overabundance of PR in solid tumors,
anti-progesterone drugs have been purposed for tumor growth
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suppression via blocking cell surface receptors, such as PR as
well as glucocorticoid receptors (GR) and ERs (Yu et al., 2015).
Cancer cell lines from several tumors such as glioma, breast,
prostate, ovary, cervix, and osteoblastoma have been treated
with mifepristone and the inhibition of the cancer cell growth
regardless of reproductive or non-reproductive origin have been
reported (Tieszen et al., 2011).
To the best of our knowledge, one of the earliest studies
on anti-progesterone administration to PCa reported in vivo
suppression of the growth of the androgen-insensitive prostatic
carcinoma within combined estrogen therapy (Mobbs and
Johnson, 1991). Later, considerable anti-tumor activity of
mifepristone was presented in both androgen-sensitive and
androgen-insensitive variants of the LNCaP via mouse models
(El Etreby et al., 2000). In addition, mifepristone was also
assessed in patients with CRPC through phase 2 study.
The combination therapy with promising agents such as
corticosteroids, ketoconazole, or 5-reductase inhibitors might be
used to block the compensatory rise in adrenal androgens and be
effective in patients with CRPC (Taplin et al., 2008).
Disulfiram
Disulfiram is the first FDA approved alcohol aversive drug
used for the treatment of alcohol dependence for more than
60 years. It inhibits the aldehyde dehydrogenase (ALDH) leading
to accumulation of acetaldehyde in blood (Kalra et al., 2014).
As a result of high-throughput cell-based drug screening,
disulfiram was found as an anti-cancer drug regarding to reduce
tumor growth in vivo and induced metallothionein expression.
Additionally, the effect of the drug was enhanced by copper
in vitro (Iljin et al., 2009). To date, numerous clinical trial studies
on administration of disulfiram were carried out to treat various
cancers such as breast, pancreas, prostate, brain, lung, melanoma
as well as metastatic types of some of them.
Disulfiram as acting like a DNA methyltransferase (DNMT1)
inhibitor provide advantage by restoring tumor suppressor genes
and leading DNA demethylation in PCa cells. It has been linked
to reductions in 5-methyl cytosine (5meC) content and decreased
methylation in APC and RARB gene promoters (Lin et al.,
2011). As follows, disulfiram has been assessed as a potential
epigenetic therapy, a pilot trial (NCT01118741) was carried out
to evaluate the effect of disulfiram on demethylating changes
with biochemically recurrent PCa via quantifying changes in
5meC content in peripheral blood mononuclear cells (PBMC)
(Schweizer et al., 2013).
Disulfiram treatment alone showed only minimal effects in
castration-resistant PCa xenografts, however, drug supplemented
with Cu2+ significantly reduced tumor growth (Safi et al., 2014).
Very recently, Skrott et al. (2017) reported that the ditiocarb
(disulfiram metabolite) and copper complex has anti-cancer
effects in vitro and in vivo. Moreover, NPL4 protein has been
proposed a molecular target which is involved in protein turnover
of tumorigenesis promoting stress-response pathways.
Leflunomide
Leflunomide is a selective inhibitor of the rate limiting step in the
de novo synthesis of pyrimidines. Teriflunomide (A77 1726) is the
active metabolite of leflunomide which suppress dihydroorotate
dehydrogenase (DHODH) activity as well as IL-1 and TNF-α. It is
used mainly for rheumatoid arthritis due to its anti-inflammatory
effects (Breedveld and Dayer, 2000).
Additionally, leflunomide has been suggested as a potent
inhibitor of tyrosine kinases and some growth factor receptors
such as EGFR, FGFR, and PDGFR. Since their activation is
associated with numerous cancer types, leflunomide has the
potential to be used as an anti-cancer agent (Gupta et al., 2013).
One of the earliest studies in which suggested anti-tumor activity
of leflunomide showed the inhibition of cancer cells including
glioma, ovarian, and prostate which express PDGFR in contrast
to cancer cell cultures which only express EGFR (Shawver
et al., 1997). Similarly, the active metabolite of leflunomide,
teriflunomide, was found more effective at inhibiting the tyrosine
kinase activity of PDGFR than that of EGFR and had no effect on
the FGFR (Xu et al., 1999).
In a phase 2 trial with leflunomide against hormone
resistant PCa, PDGFR expression was noticed in more than
80% of both metastases and primary PCas. Monotherapy of
leflunomide demonstrated PSA reduction of more than 50% of
patients and also stated significant improvement of pain (Ko
et al., 2001). In another study, preliminary results represented
chemopreventative effects of leflunomide in PCa (Hail et al.,
2010). Mono- and combination therapy of leflunomide is in phase
2/3 of clinical stage for PCa and brain and central nervous system.
Metformin
Metformin is an anti-diabetic agent primarily being used in
type 2 diabetes and increasingly in polycystic ovary syndrome
treatment. The direct effect of metformin at the molecular
level is to activate AMPK through a tumor suppressor, LKB-1,
resulting in decreased glucose level in blood. Moreover, AMPK
inhibits mTOR which is key mediator of frequently deregulated
PI3K/Akt signaling pathway in malignant cells and activates
tumor suppressor p53 leading to cancer cell apoptosis. Indirect
effect of the drug is inhibition of hepatic gluconeogenesis and
reduces insulin resistance in peripheral tissue. Since tumor cells
express high levels of the insulin receptor, reduced insulin levels
associated with metformin use provide better prognosis for a
number of cancers, including breast, colon, and PCa (Evans et al.,
2005; Whitburn et al., 2017). Metformin were reported as an anti-
cancer agent against breast, prostate, lung, cervix, and ovarian
cancer cells, up to the date. It is also in phase 1–4 clinical trials
for various cancers such as lung, prostate, breast, liver, pancreatic,
and brain (Jalving et al., 2010).
First epidemiological studies demonstrated metformin as
a potent anti-cancer agent in reducing cancer incidence and
mortality considering numerous anti-neoplastic biological effects
via a range of molecular mechanisms. Some studies supported
the oncogenic benefit of metformin for PCa patients regardless
their diabetic status (Noto et al., 2012), some of them emphasized
heterogeneous and biased results or no significant effects on
incidence of PCa (Margel et al., 2013). Since there are plenty of
investigations, the current evidences were recently summarized
a role for metformin in PCa therapy (Whitburn et al., 2017).
Besides, Electronic Health Records were assessed the use of
Frontiers in Physiology | www.frontiersin.org 11 May 2018 | Volume 9 | Article 500
fphys-09-00500 May 12, 2018 Time: 14:44 # 12
Turanli et al. Repurposing Non-cancer Drugs for Prostate Cancer
metformin and suggested an association with decreased mortality
after a cancer diagnosis compared with diabetic and non- diabetic
cancer patients (Xu et al., 2015).
Every single anti-diabetic drug does not show the similar
tendency as an anti-cancer agent. The use of metformin was
linked with reduced risk of PCa diagnosis, whereas other
oral diabetic medications had no effect (Preston et al., 2014).
Combination therapy was also another option to use metformin
in cancer treatment. Hirsch et al. (2013) showed that combination
of metformin with chemotherapy might obstruct tumor growth
and prevent recurrence of PCa cells associated with blocking
inflammatory pathways in xenograft models. Recent study
showed that metformin and VPA synergistically repressed the
proliferation in both LNCaP and PC-3. The combination therapy
was also found to cause increased apoptosis in patient-derived
prostate tumor explants. Concisely, two drugs have been
suggested that working synergistically to destroy more PCa cells
than either monotherapies alone (Tran et al., 2017).
Zoledronic Acid
Zoledronic acid (ZA) is an aminobisphosphonate with high
affinity for bone mineral and approved for the treatment
of bone related diseases such as osteoporosis. When it is
administered intravenously, it quickly localizes to bone and
inhibits osteoclastic bone resorption by negative regulation of
the action of the farnesyl pyrophosphate synthase enzyme in
the mevalonate pathway (Lewiecki, 2009). Zoledronic acid is the
first bisphosphonate with displayed efficacy in the treatment of
bone metastases of patients with a broad range of tumor types
including breast, prostate, and lung and in multiple myeloma as
well as hypercalcemia of malignancy. It also reduces incidence of
skeletal relevant complications and palliate the pain in patients
with bone metastasis (Perry and Figgitt, 2004). In addition to
other cancer types, there are more than 50 phase 4 clinical trials
which are completed for PCa and bone metastasis according to
https://clinicaltrials.gov.
The anti-cancer mechanisms of ZA may comprise apoptosis
associated with the mevalonate pathway, activation of caspases,
effects on invasiveness of the target cells, and arbitrated by
changes in expression and activity of metalloproteinases (Corey
et al., 2003). Considering PCa, ZA effectively prevents both bone
loss in patients with locally advanced disease receiving androgen
deprivation therapy and skeletal complications in men with
hormone-refractory metastatic disease. Moreover, it assumed
gold standard medication for the prevention and treatment of
skeletal complications in patients with bone metastases due to
all solid tumors with an acceptable safety profile and tolerability
(Polascik and Mouraviev, 2008).
The ZA has known anti-PCa effects, demonstrated both
preclinically with in vitro and in vivo studies (Corey et al., 2003)
and clinically through placebo-controlled trials and long-term
efficacy for the prevention of skeletal complications in later-stage
disease (Saad et al., 2002, 2004). Combination therapy ZA with
docetaxel demonstrated major improvements in survival of PCa
patients (James et al., 2016), and recently, COX-2 inhibitors
such as celecoxib and ZA therapy considered complementary
for the treatment of advanced or metastatic PCa but findings
showed no overall evidence of improved survival within the
combinatorial therapy (Mason et al., 2017). ZA is generally
used every 3 weeks based on initial clinical trials, however, the
current evidences suggested similar outcomes with a reasonable
biochemical response when ZA is used every 12 weeks in men
with bone metastases from CRPC. Less frequent treatments may
release the side effects, inconvenience, and cost (Niraula et al.,
2018).
SYSTEMS BIOLOGY PERSPECTIVE IN
DRUG DISCOVERY FOR PROSTATE
CANCER
The preliminary drug targeting approaches were correlating
diseases with the precise genetic malfunctions and subjected
to discover only the drugs that modulate these gene targets.
This reductionist point of view has not been totally successful
since the biology behind diseases is complex and diseases
are rarely up to single protein or gene (Schneider and
Klabunde, 2013). In this manner, systems biology as a holistic
approach can handle abundancy of high-throughput data
from diverse omics techniques and other sources as well as
their processes via mathematical modeling, and computational
analysis tools (Figure 3A) (Mardinoglu and Nielsen, 2015;
Zhang and Hua, 2016; Benfeitas et al., 2017; Mardinoglu et al.,
2018a).
To date, systems biology approaches have been applied to
decipher the disease mechanism and therapy options (Lee et al.,
2016, 2017; Mardinoglu et al., 2017, 2018b). As an example,
network biology approach called mode-of-action by network
identification was used to identify the mediator genes and
pathways in both primary and metastatic prostate tumors (Ergün
et al., 2007). Besides, regulatory modular networks based on
disease-specific miRNA-mRNA correlation were constructed to
explore substantial variation across primary and metastatic
prostate tumors (Zhang et al., 2012). Systems biology approaches
also enable to discover potent biomarkers for predicting PCa
outcomes as Ummanni et al. (2011) revealed novel protein
biomarkers such as eIF4A3, DDAH1, ARG2, Prdx3, and Prdx4
associated with altered proteomic expression in PCa compared
to benign prostate. There are also integrative studies combining
multi-platform and multi-dimensional datasets. Comprehensive
study utilizing different omics data from miRNA, mRNA, and
protein expressions to copy number alterations was used for the
effective stratification of patients with primary prostate tumor
(Abeshouse et al., 2015). In another study, habitual genomics and
transcriptomics data were integrated with phosphoproteomic to
identify significant kinase signaling networks in advanced PCa
(Tan et al., 2016).
The two fundamental approaches of systems biology, the “top-
down” and “bottom-up” methods, are also applicable to the drug
design and discovery in addition to other application such as
network biology, biomarker discovery, etc. As pointed out in
Figure 3B, top-down systems biology approaches aim to analyze
high-throughput omics datasets to elucidate networks and logic
behind the biological phenomena. From the drug discovery
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FIGURE 3 | The use of system biology in the drug repositioning. (A) Potential data accumulation to be used in systems biology based approaches. (B) The
application of two fundamental approaches in systems biology for drug design and discovery.
perspective, top-down methods provide detailed understanding
of the causes of disease via perturbed networks and identifying
reporter signatures as candidate biomarkers or drug targets.
As an example of top-down methods, Jin et al. (2012) used
transcriptional responses in PC-3 cells as well as MCF7 and HL60
before and after drug treatment. They developed drug off-target-
based hybrid method that combines Bayesian factor regression
model and network component called cancer-signaling bridges
to analyze transcriptome data associated with drug usage. On
the other hand, bottom-up methods object to simulate nature
by utilizing known parameters and generating models of living
cells. Each individual components of a system are gathered
into a generated network to chase dynamic properties at the
system level. Different computational modeling methods such
as ODE-based, logic-based, or stoichiometric modeling can be
applicable to investigate drug mechanism, its responses, and
side effects. Gallaher et al. (2014) designed a computational
model to predict patient outcome due to therapy response.
They highlighted that such models and/or genetic algorithms are
particularly useful for oncologists to predict the therapy response
or drug combination therapies for effective treatment and cure of
metastatic castrate resistant PCa patients.
Since the metabolic changes are quite important to detect and
treat PCa regardless the disease stage (Eidelman et al., 2017),
genome-scale metabolic models (GEMs) might be a very helpful
source to create and/or test the hypothesis for drug repositioning
in addition to elucidation of physiological mechanisms or side
effects (Mardinoglu and Nielsen, 2012; Zhang and Hua, 2016)
so GEMs can be used as a tool in both “top-down” and
“bottom-up” methods in the context of drug discovery. GEMs
have been employed for studying cancer metabolism utilizing
either generic/personalized or tumor/cell-specific which may
translate into clinically relevant applications. They can also be
used to identify drug targets leading inhibition of cancer-related
phenotypes or drug resistance in cancer therapy. Furthermore,
the fortification of GEMs can be obtained via integration of
omics data like genomic, transcriptomic, and proteomic as well
as incorporation of regulatory molecules to the metabolism
(Lee et al., 2018). GEMs also provide valuable insight on the
interaction between cancer cells and supporting cells in their
niches as paving the way for whole-cell modeling (Ghaffari
et al., 2015; Yizhak et al., 2015). There are valuable GEMs
studies for drug-related purposes. Metabolic transformation
algorithm (MTA) was purposed to search for drug targets that
could restore the metabolism within the cell from the disease
state to the healthy state (Yizhak et al., 2013). Agren et al.
(2014) revised the INIT algorithm to tINIT and used this for
reconstruction of personalized GEMs for HCC patients and
83 healthy cell types via integration of proteomics data and
HMR 2.0 (Mardinoglu et al., 2014). Reconstructed personalized
GEMs were used to identify selective anti-metabolites for
cancer therapy. GEMs were also used for predicting drug
side effects and the identification of key metabolic reactions
and biomarkers via implementation of model-based phenotype
predictor approach that leverages medical informatics resources
and GEMs (Shaked et al., 2016). PCa-specific generic GEM
(Agren et al., 2012) and personalized GEMs for PCa patients
(Uhlen et al., 2017) have been reconstructed for revealing
the molecular mechanism of the tumor progression. They
developed INIT algorithm and used HMR 2.0 to reconstruct
cell type–specific metabolic models with information on protein
abundances from the Human Proteome Atlas. Very recently,
GEMs for two clonal subpopulations from PC-3 cell line were
modeled to explore their metabolic differences. Highly invasive,
low metastatic PC-3/S, and highly metastatic, low invasive
PC-3/M cells present the opposite phenotype. Addition to
unveiling key metabolic nodes related to tumor heterogeneity,
results also highlighted potential subpopulation-specific targets
with potential therapeutic implications. Such model for PC-3/M
cells showed sensitivity to etomoxir, an inhibitor of long-chain
fatty acid transport to the mitochondria (Marin de Mas et al.,
2018).
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FUTURE DIRECTIONS
Known non-cancer drugs with new therapeutic applications in
oncology has been reviewed in detail comprising drug mode
of actions, rationale behind the approaches, practical evidences
such as preclinical or clinical studies, and opportunities for
repurposing drugs as anti-cancer agents (Gupta et al., 2013; Shim
and Liu, 2014; Bhattarai et al., 2016; Würth et al., 2016).
Drugs from knowledge- and activity-based methods were
quite more applied than in silico methods. Since the available
drug libraries were already tested for PCa and there is still the
need of expanded new drug libraries, these methods could be
in bottleneck, however, in silico methods were not elaborated,
yet but showed high potential for validation of drugs as well as
discovery process which might be achieved via computational
methods. Several studies have been discussing in silico methods
and their integrations in detail (Jiao et al., 2015; Hodos et al.,
2016; March-Vila et al., 2017; Vanhaelen et al., 2017).
Gut microbiota has a crucial role in drug efficacy both directly
and indirectly. Hence, diet has also enormous influence on the
gut microbiota, pioneering computational models comprising
xenobiotic metabolism and microbial enzymes (Shoaie et al.,
2015) should be constructed for integrating diet-microbiota-
drug interactions and evaluated in the context of PCa treatment
(Thiele et al., 2017).
Current standard treatment strategy for localized PCa consists
of prostatectomy, RT supplemented with hormone therapy.
However, recurrence after surgery or formation of castration-
resistant PCa after hormone therapy is common. Chemotherapy
has merely moderate effect for the treatment of metastatic
tumor. Most of the drugs (repurposed or already used in clinic)
target growth factors and/or their receptors, which are abundant
in tumors. Some of them modulate survival, angiogenesis,
or downstream signaling pathways. In general, researchers
focused on metastatic PCa more than primary tumor because
of high mortality and poor survival rates. However, primary
prostate tumor with intermediate or high-risk score cause higher
mortality regardless of initial therapy (Fu et al., 2012).
The most lethal form of PCa is considered as metastatic
castration-resistant PCa whereas it is progressed form of primary
tumors. Therefore, effective treatment strategies on prostate
primary tumors are as important as on metastatic ones. The use
of GEMs to detect metabolic alterations and their drug targets
is already discussed in this review. However, there is a need for
comprehensive model which presents not only metastatic PCa
but also primary PCa. On the other hand, omics data integration
is a significant value for a metabolic model in which generally
transcriptomics and proteomics have utilized mainly. Whether
GEMs are deliberated as generic disease–specific model, it is
also important to represent each individual difference inside.
Considering key stones, GEMs should be more evaluated for drug
repositioning in the future.
Although DR is generally emphasized within advantages,
many challenges deserve attention. Not all approved non-cancer
drugs should be tested for cancer treatment without valid
molecular insights into their potent efficacies. There are also
several studies that take into account abandoned drugs for
repurposing, however, extra care in selecting abandoned drugs
is recommended regarding insufficient pharmacokinetic and
pharmacodynamic data. Another point is uncertainties whether
FIGURE 4 | Proposed anti-cancer mechanisms of clinically evaluated repurposed drug candidates.
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drug doses, formulations, and routes of administration for the
original indication are similar to the need of the anti-cancer
indication. Although approved drug acquired via DR methods
do not work as expected, structures and targets of the approved
drugs can also help in designing improved drug with new
properties such as better water solubility, increased selectivity,
long retention time, etc.
Although DR should significantly reduce the time and cost,
considering the obstacles associated with phase 2 and 3 clinical
trials, failure in these phases cannot be reduced by DR. Much
money, larger number of patients and longer time is still
needed after phase 2 of clinical trial with existing failure
chance, unfortunately. Intellectual property right and regulatory
standards comprising the discussions on off-patent drugs and
their mechanism of action (MOU) patents are another issue
considered for the commercialization of new cancer indication
of an already approved drug as previously mentioned (Shim and
Liu, 2014; Jiao et al., 2015; Bhattarai et al., 2016).
As we have mentioned in the study, North American
studies reported a decreased risk of PCa (Vidal et al., 2015),
whereas studies from Europe found elevated risk due to
the use of any NSAID. Therefore, population and variations
based on geographic region could be another challenge for
DR. However, particularly in silico DR methodologies based
on signature matching techniques might give expression
signatures for each individual and expectedly translate into
a personalized DR (Li and Jones, 2012; Hodos et al.,
2016).
The DR provide significant opportunities to establish novel
collaborations between academia and pharmaceutical industry.
Moreover, there are some recent examples as mentioned
previously. The National Institutes of Health has collaborated
with pharmaceutical companies to investigate almost 60
abandoned drugs for new clinical purposes. Likewise, the
United Kingdom Medical Research Council is making million
dollars investments to the United Kingdom researchers for
investigation of 22 abandoned compounds (Gupta et al.,
2013).
CONCLUSION
In this review, we highlighted repurposed non-cancer drugs and
their mechanisms to treat PCa through diverse perspectives.
Among these repurposed drugs, 10 drugs were obtained through
different drug repositioning approaches as we categorized in
3: knowledge-based, activity-based, and in silico DR methods
(Table 1). Most of them have shown anti-cancer activity only
in preclinical studies. However, these observations will translate
into the clinic remains to be seen. Another 14 drugs and 1
drug family (statins) were discussed in detail with a particular
emphasis on non-cancer drugs under clinical investigation for
PCa, up to the date (Table 3). Since drugs summarized in Table 3
have already completed several phases of clinical trials, the known
safety profiles of these drugs decrease their chances of failure to
become an approved drug.
Mono- or combination therapy of these medications have
shown anti-cancer and palliative activities in cancer patients.
To the best of our knowledge, there are a few drugs such as
thalidomide, celecoxib, methotrexate which have been approved
for treatment of cancer patients, in addition to their original uses.
However, zoledronic acid is the only repurposed and approved
non-cancer drug for PCa patients this far. Anti-cancer activities
of existing drugs shown in this study cover diverse mechanisms
such as inhibition of mTOR and VEGFR2 signaling, PI3K/Akt
signaling inhibition, COX and selective COX-2 inhibition, NF-
κB inhibition, Wnt/β-Catenin pathway inhibition, DNMT1
inhibition, GSK-3β inhibition, suppression of anti-apoptotic
proteins, tyrosine kinases and some growth factor inhibition,
HIF-1α suppression, tumor angiogenesis reduction, and matrix
metalloproteinases enzyme inhibition to resist invasion and
metastasis (Figure 4).
Most of the repurposing studies summarized in this study
were targeting metastatic or advanced PCa cases in which
mortality rates were high and hormone therapy as far as
medications do not help. However, treatment of primary tumors
and prevention of the disease should also be considered in the
context of drug repositioning. We anticipate that this review
article will not only shed a light on current repurposed drugs
but also help researchers in repurposing more therapeutics from
already approved non-cancer drugs in the future.
AUTHOR CONTRIBUTIONS
BT wrote the manuscript. AM and KA conceived the study. All
authors contributed to the manuscript during the progress of the
work.
FUNDING
This work was supported by TUBITAK, project numbers 2214/A-
1059B141600581 and 117S489, and funded by Knut and Alice
Wallenberg Foundation.
ACKNOWLEDGMENTS
Even though we aimed to be comprehensive, we sincerely
apologize to our colleagues whose work could not be cited
because of space considerations.
REFERENCES
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., et al. (2015).
The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025.
doi: 10.1016/j.cell.2015.10.025
Abou El-Magd, R., Park, H., Kawazoe, T., Iwana, S., Ono, K., Chung, S.,
et al. (2010). The effect of risperidone on D-amino acid oxidase activity
as a hypothesis for a novel mechanism of action in the treatment of
schizophrenia. J. Psychopharmacol. 24, 1055–1067. doi: 10.1177/0269881109
102644
Frontiers in Physiology | www.frontiersin.org 15 May 2018 | Volume 9 | Article 500
fphys-09-00500 May 12, 2018 Time: 14:44 # 16
Turanli et al. Repurposing Non-cancer Drugs for Prostate Cancer
Aftab, B. T., Dobromilskaya, I., Liu, J. O., and Rudin, C. M. (2011). Itraconazole
inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer
Res. 71, 6764–6772. doi: 10.1158/0008-5472.CAN-11-0691
Agren, R., Bordel, S., Mardinoglu, A., Pornputtapong, N., Nookaew, I., and
Nielsen, J. (2012). Reconstruction of genome-scale active metabolic networks
for 69 human cell types and 16 cancer types using INIT. PLoS Comput. Biol.
8:e1002518. doi: 10.1371/journal.pcbi.1002518
Agren, R., Mardinoglu, A., Asplund, A., Kampf, C., Uhlen, M., and Nielsen, J.
(2014). Identification of anticancer drugs for hepatocellular carcinoma through
personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10:721.
doi: 10.1002/msb.145122
Antonarakis, E. S., Heath, E. I., Smith, D. C., Rathkopf, D., Blackford, A. L.,
Danila, D. C., et al. (2013). Repurposing itraconazole as a treatment for
advanced prostate cancer: a noncomparative randomized phase II trial in men
with metastatic castration-resistant prostate cancer. Oncologist 18, 163–173.
doi: 10.1634/theoncologist.2012-314
Assayag, J., Pollak, M. N., and Azoulay, L. (2015). The use of aspirin and the
risk of mortality in patients with prostate cancer. J. Urol. 193, 1220–1225.
doi: 10.1016/j.juro.2014.11.018
Ataie-Kachoie, P., Morris, D. L., and Pourgholami, M. H. (2013). Minocycline
suppresses interleukine-6, its receptor system and signaling pathways and
impairs migration, invasion and adhesion capacity of ovarian cancer cells:
in vitro and in vivo studies. PLoS One 8:e60817. doi: 10.1371/journal.pone.
0060817
Ayan, D., Maltais, R., and Poirier, D. (2012). Identification of a 17β-hydroxysteroid
dehydrogenase type10 steroidal inhibitor: a tool to investigate the role of type10
in Alzheimer’s disease and prostate cancer. ChemMedChem 7, 1181–1184.
doi: 10.1002/cmdc.201200129
Benfeitas, R., Uhlen, M., Nielsen, J., and Mardinoglu, A. (2017). New challenges
to study heterogeneity in cancer redox metabolism. Front. Cell Dev. Biol. 5:65.
doi: 10.3389/fcell.2017.00065
Bhattarai, D., Singh, S., Jang, Y., Han, S. H., Lee, K., and Choi, Y. (2016). An
insight into drug repositioning for the development of novel anti-cancer drugs.
Curr. Top. Med. Chem. 16, 2156–2168. doi: 10.2174/156802661666616021615
3618
Bilani, N., Bahmad, H., and Abou-Kheir, W. (2017). Prostate cancer and aspirin
use: Synopsis of the proposed molecular mechanisms. Front. Pharmacol. 8:145.
doi: 10.3389/fphar.2017.00145
Breedveld, F. C., and Dayer, J.-M. (2000). Leflunomide: mode of action in the
treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59, 841–849. doi: 10.1136/
ard.59.11.841
Brodie, S. A., and Brandes, J. C. (2014). Could valproic acid be an effective
anticancer agent? The evidence so far. Expert Rev. Anticancer Ther. 14,
1097–1100. doi: 10.1586/14737140.2014.940329
Buttgereit, F., Burmester, G. R., Straub, R. H., Seibel, M. J., and Zhou, H. (2011).
Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis
Rheum. 63, 1–9. doi: 10.1002/art.30070
Calderón-Montaño, J., Estefanía, B.-M., Manuel Luis, O., and Maldonado-
Navas, D. (2014). Evaluating the cancer therapeutic potential of cardiac
glycosides. Biomed Res. Int. 2014:794930. doi: 10.1155/2014/794930
Caon, J., Paquette, M., Hamm, J., and Pickles, T. (2014). Does statin or ASA affect
survival when prostate cancer is treated with external beam radiation therapy?
Prostate Cancer 2014, 184297. doi: 10.1155/2014/184297
Chan, K. K. W., Oza, A. M., and Siu, L. L. (2003). The statins as anticancer agents.
Clin. Cancer Res. 9, 10–19. doi: 10.1158/1078-0432.ccr-13-1524
Chang, W.-L., Hsu, L.-C., Leu, W.-J., Chen, C.-S., and Guh, J.-H. (2015).
Repurposing of nitroxoline as a potential anticancer agent against human
prostate cancer - a crucial role on AMPK/mTOR signaling pathway and the
interplay with Chk2 activation. Oncotarget 6, 39806–39820. doi: 10.18632/
oncotarget.5655
Chong, C., and Sullivan, D. J. (2007). New uses for old drugs. Nature 448, 645–646.
doi: 10.1038/448645a
Chong, C. R., Chen, X., Shi, L., Liu, J. O., and Sullivan, D. J. (2006a). A clinical drug
library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2,
415–416. doi: 10.1038/nchembio806
Chong, C. R., Qian, D. Z., Pan, F., Wei, Y., Pili, R., Sullivan, D. J., et al.
(2006b). Identification of type 1 inosine monophosphate dehydrogenase as
an antiangiogenic drug target. J. Med. Chem. 49, 2677–2680. doi: 10.1021/
jm051225t
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., and Liu, J. O. (2007). Inhibition of
angiogenesis by the antifungal drug itraconazole. ACS Chem. Biol. 2, 263–270.
doi: 10.1021/cb600362d
Chu, C. C., Hsing, C. H., Shieh, J. P., Chien, C. C., Ho, C. M., and Wang, J. J.
(2014). The cellular mechanisms of the antiemetic action of dexamethasone
and related glucocorticoids against vomiting. Eur. J. Pharmacol. 722, 48–54.
doi: 10.1016/j.ejphar.2013.10.008
Corey, E., Brown, L. G., Quinn, J. E., Poot, M., Roudier, M. P., Higano, C. S., et al.
(2003). Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic
metastases of prostate cancer. Clin. Cancer Res. 9, 295–306.
Davies, N. M., McLachlan, A. J., Day, R. O., and Williams, K. M. (2000).
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective
cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 38, 225–242. doi: 10.2165/
00003088-200038030-00003
Deotarse, P. P., Jain, A. S., Baile, M. B., Kolhe, N. S., and Kulkarni, A. A. (2015).
Drug repositioning: a review. Int. J. Pharma Res. Rev. 4, 51–58.
Dilly, S. J., Clark, A. J., Marsh, A., Mitchell, D. A., Cain, R., Fishwick, C. W. G.,
et al. (2017). A chemical genomics approach to drug reprofiling in oncology:
antipsychotic drug risperidone as a potential adenocarcinoma treatment.
Cancer Lett. 393, 16–21. doi: 10.1016/j.canlet.2017.01.042
Downer, M. K., Allard, C. B., Preston, M. A., Gaziano, J. M., Stampfer, M. J., Mucci,
L. A., et al. (2017). Regular aspirin use and the risk of lethal prostate cancer
in the physicians’ Health Study. Eur. Urol. 72, 821–827. doi: 10.1016/j.eururo.
2017.01.044
Eidelman, E., Twum-Ampofo, J., Ansari, J., and Siddiqui, M. M. (2017). The
metabolic phenotype of prostate cancer. Front. Oncol. 7:131. doi: 10.3389/fonc.
2017.00131
El Etreby, M. F., Liang, Y., and Lewis, R. W. (2000). Induction of apoptosis
by mifepristone and tamoxifen in human LNCaP prostate cancer cells in
culture. Prostate 43, 31–42. doi: 10.1002/(SICI)1097-0045(20000401)43:1<31::
AID-PROS5>3.0.CO;2-#
Elder, D. J. E., Halton, D. E., Crew, T. E., and Paraskeva, C. (2000). Apoptosis
induction and cyclooxygenase-2 regulation in human colorectal adenoma
and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal
anti-inflammatory drug Ns-398. Int. J. Cancer 86, 553–560. doi: 10.1002/(SICI)
1097-0215(20000515)86:4<553::AID-IJC18>3.0.CO;2-9
Ergün, A., Lawrence, C. A., Kohanski, M. A., Brennan, T. A., and Collins, J. J.
(2007). A network biology approach to prostate cancer. Mol. Syst. Biol. 3:82.
doi: 10.1038/msb4100125
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., and Morris,
A. D. (2005). Metformin and reduced risk of cancer in diabetic patients. Br.
Med. J. 330, 1304–1305. doi: 10.1136/bmj.38415.708634.F7
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al.
(2015). Cancer incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386. doi: 10.1002/ijc.
29210
Fowke, J. H., Motley, S. S., Smith, J. A., Cookson, M. S., Concepcion, R., Chang,
S. S., et al. (2009). Association of nonsteroidal anti-inflammatory drugs, prostate
specific antigen and prostate volume. J. Urol. 181, 2064–2070. doi: 10.1016/j.
juro.2009.01.031
Fu, W., Madan, E., Yee, M., and Zhang, H. (2012). Progress of molecular
targeted therapies for prostate cancers. Biochim. Biophys. Acta 1825, 140–152.
doi: 10.1016/j.bbcan.2011.11.003
Gallaher, J., Cook, L. M., Gupta, S., Araujo, A., Dhillon, J., Park, J. Y., et al.
(2014). Improving treatment strategies for patients with metastatic castrate
resistant prostate cancer through personalized computational modeling. Clin.
Exp. Metastasis 31, 991–999. doi: 10.1007/s10585-014-9674-1
Gantt, S., Casper, C., and Ambinder, R. F. (2013). Insights into the broad cellular
effects of nelfinavir and the HIV protease inhibitors supporting their role in
cancer treatment and prevention. Curr. Opin. Oncol. 25, 495–502. doi: 10.1097/
CCO.0b013e328363dfee
Garrido-Mesa, N., Zarzuelo, A., and Gálvez, J. (2013). Minocycline: Far beyond an
antibiotic. Br. J. Pharmacol. 169, 337–352. doi: 10.1111/bph.12139
Gayvert, K. M., Dardenne, E., Cheung, C., Boland, M. R., Lorberbaum, T.,
Wanjala, J., et al. (2016). A computational drug repositioning approach for
Frontiers in Physiology | www.frontiersin.org 16 May 2018 | Volume 9 | Article 500
fphys-09-00500 May 12, 2018 Time: 14:44 # 17
Turanli et al. Repurposing Non-cancer Drugs for Prostate Cancer
targeting oncogenic transcription factors. Cell Rep. 15, 2348–2356. doi: 10.1016/
j.celrep.2016.05.037
Ghaffari, P., Mardinoglu, A., Asplund, A., Shoaie, S., Kampf, C., Uhlen, M., et al.
(2015). Identifying anti-growth factors for human cancer cell lines through
genome-scale metabolic modeling. Sci. Rep. 5:8183. doi: 10.1038/srep08183
Giridhar, R. (2012). Drug discovery: past and present. J. Adv. Pharm. Technol.
Res. 3:2.
Gonnissen, A., Isebaert, S., McKee, C. M., Dok, R., Haustermans, K., and Muschel,
R. J. (2016). The hedgehog inhibitor GANT61 sensitizes prostate cancer cells
to ionizing radiation both in vitro and in vivo. Oncotarget 7, 84286–84298.
doi: 10.18632/oncotarget.12483
Gottfried, E., Lang, S. A., Renner, K., Bosserhoff, A., Gronwald, W., Rehli, M.,
et al. (2013). New aspects of an old drug - diclofenac targets MYC and glucose
metabolism in tumor cells. PLoS One 8:e66987. doi: 10.1371/journal.pone.
0066987
Grösch, S., Maier, T. J., Schiffmann, S., and Geisslinger, G. (2006). Cyclooxygenase-
2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
J. Natl. Cancer Inst. 98, 736–747. doi: 10.1093/jnci/djj206
Guan, M., Su, L., Yuan, Y. C., Li, H., and Chow, W. A. (2015). Nelfinavir and
nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant
prostate cancer. Sci. Rep. 5:9698. doi: 10.1038/srep09698
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., and Aggarwal, B. B. (2013).
Cancer drug discovery by repurposing: Teaching new tricks to old dogs. Trends
Pharmacol. Sci. 34, 508–517. doi: 10.1016/j.tips.2013.06.005
Hafeez, B. B., Ganju, A., Sikander, M., Kashyap, V. K., Hafeez, Z., Bin, et al. (2017).
Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes
via inhibition of oncogenic β-catenin signaling and EMT progression.
Mol. Cancer Ther. 16, 2267–2280. doi: 10.1158/1535-7163.MCT-17-
0157
Hail, N., Chen, P., and Bushman, L. R. (2010). Teriflunomide (Leflunomide)
promotes cytostatic, antioxidant, and apoptotic effects in transformed
prostate epithelial cells: evidence supporting a role for teriflunomide in
prostate cancer chemoprevention. Neoplasia 12, 464–475. doi: 10.1593/neo.
10168
Harris, R. E., Alshafie, G. A., Abou-Issa, H., and Seibert, K. (2000).
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2
inhibitor. Cancer Res. 60, 2101–2103.
Hazra, B. G., and Pore, V. S. (2001). Mifepristone (RU-486), the recently developed
antiprogesterone drug and its analogues. J. Indian Inst. Sci. 81, 287–298.
Hindler, K. (2006). The role of statins in cancer therapy. Oncologist 11, 306–315.
doi: 10.1634/theoncologist.11-3-306
Hirsch, H. A., Iliopoulos, D., and Struhl, K. (2013). Metformin inhibits the
inflammatory response associated with cellular transformation and cancer stem
cell growth. Proc. Natl. Acad. Sci. U.S.A. 110, 972–977. doi: 10.1073/pnas.
1221055110
Hodos, R. A., Kidd, B. A., Khader, S., Readhead, B. P., and Dudley, J. T. (2016). In
silico methods for drug repurposing and pharmacology. WIREs Syst. Biol. Med.
8, 186–210. doi: 10.1002/wsbm.1337
Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M.,
and Chen, C. S. (2000). The cyclooxygenase-2 inhibitor celecoxib
induces apoptosis by blocking Akt activation in human prostate
cancer cells independently of Bcl-2. J. Biol. Chem. 275, 11397–11403.
doi: 10.1074/jbc.275.15.11397
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., et al. (2011).
The NCGC pharmaceutical collection: a comprehensive resource of clinically
approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med.
3:80ps16. doi: 10.1126/scitranslmed.3001862
Hutchinson, J., and Marignol, L. (2017). Clinical potential of statins in prostate
cancer radiation therapy. Anticancer Res. 37, 5363–5372. doi: 10.21873/
anticanres.11962
Iljin, K., Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V., et al. (2009).
High-throughput cell-based screening of 4910 known drugs and drug-like small
molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Clin. Cancer Res. 15, 6070–6078. doi: 10.1158/1078-0432.CCR-09-1035
Inoue, T., Anai, S., Onishi, S., Miyake, M., Tanaka, N., Hirayama, A., et al. (2013).
Inhibition of COX-2 expression by topical diclofenac enhanced radiation
sensitivity via enhancement of TRAIL in human prostate adenocarcinoma
xenograft model. BMC Urol. 13:1. doi: 10.1186/1471-2490-13-1
Iwamoto, Y., Ishii, K., Kanda, H., Kato, M., Miki, M., Kajiwara, S., et al. (2017).
Combination treatment with naftopidil increases the efficacy of radiotherapy
in PC-3 human prostate cancer cells. J. Cancer Res. Clin. Oncol. 143, 933–939.
doi: 10.1007/s00432-017-2367-9
Jaggi, M., Johansson, S. L., Baker, J. J., Smith, L. M., Galich, A., and Balaji, K. C.
(2005). Aberrant expression of E-cadherin and beta-catenin in human prostate
cancer. Urol. Oncol. Semin. Orig. Investig. 23, 402–406. doi: 10.1016/j.urolonc.
2005.03.024
Jaggi, M., Nazemi, T., Abrahams, N. A., Baker, J. J., Galich, A., Smith, L. M., et al.
(2006). N-cadherin switching occurs in high Gleason grade prostate cancer.
Prostate 66, 193–199. doi: 10.1002/pros.20334
Jalving, M., Gietema, J. A., Lefrandt, J. D., de Jong, S., Reyners, A. K. L., Gans,
R. O. B., et al. (2010). Metformin: Taking away the candy for cancer? Eur. J.
Cancer 46, 2369–2380. doi: 10.1016/j.ejca.2010.06.012
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears,
M. R., et al. (2016). Addition of docetaxel, zoledronic acid, or both to first-line
long-term hormone therapy in prostate cancer (STAMPEDE): survival results
from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet 387, 1163–1177. doi: 10.1016/S0140-6736(15)01037-5
Jiang, H., Taggart, J. E., Zhang, X., Benbrook, D. M., Lind, S. E., and Ding, W.-Q.
(2012). Nitroxoline (5-amino-8-hydroxyquinoline) is more a potent anticancer
agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 312, 11–17.
doi: 10.1016/j.canlet.2011.06.032.Nitroxoline
Jiao, M., Liu, G., Xue, Y., and Ding, C. (2015). Computational drug repositioning
for cancer therapeutics. Curr. Top. Med. Chem 15, 767–775. doi: 10.2174/
1568026615666150302105831
Jin, G., Fu, C., Zhao, H., Cui, K., Chang, J., and Wong, S. T. C. (2012). A novel
method of transcriptional response analysis to facilitate drug repositioning for
cancer therapy. Cancer Res. 72, 33–44. doi: 10.1158/0008-5472.CAN-11-2333
Kalra, G., de Sousa, A., and Shrivastava, A. (2014). Disulfiram in the management
of alcohol dependence: a comprehensive clinical review. Open J. Psychiatry 4,
43–52. doi: 10.1111/nyas.12538
Kar, A. (2007). Medicinal Chemistry. New Delhi: New age International Publishers.
Katz, M. S., Carroll, P. R., Cowan, J. E., Chan, J. M., and D’Amico, A. V. (2010).
Association of statin and nonsteroidal anti-inflammatory drug use with prostate
cancer outcomes: results from CaPSURE. BJU Int. 106, 627–632. doi: 10.1111/j.
1464-410X.2010.09232.x
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., et al. (2010).
Itraconazole, a commonly used antifungal that inhibits hedgehog pathway
activity and cancer growth. Cancer Cell 17, 388–399. doi: 10.1016/j.ccr.2010.
02.027
Kirschenbaum, A., Liu, X. H., Yao, S., and Levine, A. C. (2001). The role of
cyclooxygenase-2 in prostate cancer. Urology 58(2 Suppl. 1), 127–131. doi:
10.1016/S0090-4295(01)01255-9
Ko, Y. J., Small, E. J., Kabbinavar, F., Chachoua, A., Taneja, S., Reese, D., et al.
(2001). A multi-institutional phase ii study of SU101, a platelet-derived growth
factor receptor inhibitor, for patients with hormone-refractory prostate cancer.
Clin. Cancer Res. 7, 800–805.
Koltai, T. (2015). Fenofibrate in cancer: mechanisms involved in anticancer
activity. F1000Research 4:55. doi: 10.12688/f1000research.6153.2
Kondratskyi, A., Kondratska, K., Vanden Abeele, F., Gordienko, D., Dubois, C.,
Toillon, R. A., et al. (2017). Ferroquine, the next generation antimalarial
drug, has antitumor activity. Sci. Rep. 7:15896. doi: 10.1038/s41598-017-
16154-2
Kulp, S. K., Yang, Y., Hung, C., Chen, K., Lai, J., Tseng, P., et al. (2004). 3-
Phosphoinositide-dependent protein kinase-1 / Akt signaling represents a
major cyclooxygenase-2-independent target for celecoxib in prostate cancer
cells 3-phosphoinositide-dependent protein kinase-1 / Akt signaling represents
a major cyclooxygenase-2-I. Cancer Res. 64, 1444–1451. doi: 10.1158/0008-
5472.CAN-03-2396
Leahy, K. M., Ornberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer,
J. L. (2002). Cyclooxygenase-2 inhibition by celecoxib reduces proliferation
and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62,
625–631.
Lee, J. E., and Kim, J. H. (2015). Valproic acid inhibits the invasion of
PC3 prostate cancer cells by upregulating the metastasis suppressor protein
NDRG1. Genet. Mol. Biol. 38, 527–533. doi: 10.1590/S1415-4757384201
50028
Frontiers in Physiology | www.frontiersin.org 17 May 2018 | Volume 9 | Article 500
fphys-09-00500 May 12, 2018 Time: 14:44 # 18
Turanli et al. Repurposing Non-cancer Drugs for Prostate Cancer
Lee, S., Zhang, C., Arif, M., Liu, Z., Benfeitas, R., Bidkhori, G., et al. (2018). TCSBN:
A database of tissue and cancer specific biological networks. Nucleic Acids Res.
46, D595–D600. doi: 10.1093/nar/gkx994
Lee, S., Zhang, C., Kilicarslan, M., Piening, B. D., Bjornson, E., Hallström, B. M.,
et al. (2016). Integrated network analysis reveals an association between plasma
mannose levels and insulin resistance. Cell Metab. 24, 172–184. doi: 10.1016/j.
cmet.2016.05.026
Lee, S., Zhang, C., Liu, Z., Klevstig, M., Mukhopadhyay, B., Bergentall, M., et al.
(2017). Network analyses identify liver-specific targets for treating liver diseases.
Mol. Syst. Biol. 13:938. doi: 10.15252/msb.20177703
Levy, C. W., Roujeinikova, A., Sedelnikova, S., Baker, P. J., Stuitje, A. R., Slabas,
A. R., et al. (1999). Molecular basis of triclosan activity. Nature 398, 383–384.
doi: 10.1038/18803
Lewiecki, E. M. (2009). Intravenous zoledronic acid for the treatment of
osteoporosis: the evidence of its therapeutic effect. Core Evid. 4, 13–23.
doi: 10.2147/CE.S6011
Li, Y. Y., and Jones, S. J. (2012). Drug repositioning for personalized medicine.
Genome Med. 4:27. doi: 10.1186/gm326
Lin, J., Haffner, M. C., Zhang, Y., Lee, B. H., Brennen, W. N., Britton, J., et al.
(2011). Disulfiram is a DNA demethylating agent and inhibits prostate cancer
cell growth. Prostate 71, 333–343. doi: 10.1002/pros.21247
Lin, J., Zhan, T., Duffy, D., Hoffman-Censits, J., Kilpatrick, D., Trabulsi, E. J.,
et al. (2014). A pilot phase II study of digoxin in patients with recurrent
prostate cancer as evident by a rising PSA. Am. J. cancer Ther. Pharmacol. 2,
21–32.
Liu, Y., Chen, J. Q., Xie, L., Wang, J., Li, T., He, Y., et al. (2014). Effect of aspirin
and other non-steroidal anti-inflammatory drugs on prostate cancer incidence
and mortality: a systematic review and meta-analysis. BMC Med. 12:55.
doi: 10.1186/1741-7015-12-55
Lokeshwar, B. L. (2011). Chemically modified non-antimicrobial tetracyclines are
multifunctional drugs against advanced cancers. Pharmacol. Res. 63, 146–150.
doi: 10.1016/j.phrs.2010.11.003
Lopez-Lazaro, M. (2009). Digoxin, HIF-1, and cancer. Proc. Natl. Acad. Sci. U.S.A.
106:E26. doi: 10.1073/pnas.0813047106
Lu, W., Lin, C., Roberts, M. J., Waud, W. R., Piazza, G. A., and Li, Y. (2011).
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6
degradation and inhibiting the Wnt/β-catenin pathway. PLoS One 6:e29290.
doi: 10.1371/journal.pone.0029290
Mahmud, S. M., Franco, E. L., and Aprikian, A. G. (2010). Use of nonsteroidal anti-
inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer 127,
1680–1691. doi: 10.1002/ijc.25186
Marcella, S. W., David, A., Ohman-Strickland, P. A., Carson, J., and Rhoads, G. G.
(2012). Statin use and fatal prostate cancer: a matched case-control study.
Cancer 118, 4046–4052. doi: 10.1002/cncr.26720
March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H.,
et al. (2017). On the integration of in silico drug design methods
for drug repurposing. Front. Pharmacol. 8:298. doi: 10.3389/fphar.2017.
00298
Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., and Nielsen, J.
(2014). Genome-scale metabolic modelling of hepatocytes reveals serine
deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun.
5:3083. doi: 10.1038/ncomms4083
Mardinoglu, A., Bjornson, E., Zhang, C., Klevstig, M., Söderlund, S., Ståhlman, M.,
et al. (2017). Personal model-assisted identification of NAD + and glutathione
metabolism as intervention target in NAFLD. Mol. Syst. Biol. 13:916.
doi: 10.15252/msb.20167422
Mardinoglu, A., Boren, J., Smith, U., Uhlen, M., and Nielsen, J. (2018a). Systems
biology in hepatology: approaches and applications. Nat. Rev. Gastroenterol.
Hepatol. (in press). doi: 10.1038/s41575-018-0007-8
Mardinoglu, A., and Nielsen, J. (2012). Systems medicine and metabolic modelling.
J. Int. Med. 271, 142–154. doi: 10.1111/j.1365-2796.2011.02493.x
Mardinoglu, A., and Nielsen, J. (2015). New paradigms for metabolic modeling
of human cells. Curr. Opin. Biotechnol. 34, 91–97. doi: 10.1016/j.copbio.2014.
12.013
Mardinoglu, A., Wu, H., Bjornson, E., Zhang, C., Hakkarainen, A., Räsänen, S. M.,
et al. (2018b). An integrated understanding of the rapid metabolic benefits of
a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab. 27,
559.e5–571.e5. doi: 10.1016/j.cmet.2018.01.005
Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G., Austin, P. C.,
et al. (2013). Metformin use and all-cause and prostate cancer-specific mortality
among men with diabetes. J. Clin. Oncol. 31, 3069–3075. doi: 10.1200/JCO.2012.
46.7043
Marin de Mas, I., Aguilar, E., Zodda, E., Balcells, C., Marin, S., Dallmann, G.,
et al. (2018). Model-driven discovery of long-chain fatty acid metabolic
reprogramming in heterogeneous prostate cancer cells. PLoS Comput. Biol.
14:e1005914. doi: 10.1371/journal.pcbi.1005914
Mason, M. D., Clarke, N. W., James, N. D., Dearnaley, D. P., Spears, M. R., Ritchie,
A. W. S., et al. (2017). Adding celecoxib with or without zoledronic acid for
hormone-naïve prostate cancer: long-term survival results from an adaptive,
multiarm, multistage, platform, randomized controlled trial. J. Clin. Oncol. 35,
1530–1541. doi: 10.1200/JCO.2016.69.0677
Masumori, N. (2011). Naftopidil for the treatment of urinary symptoms in
patients with benign prostatic hyperplasia. Ther. Clin. Risk Manage. 7, 227–238.
doi: 10.2147/TCRM.S13883
McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M.,
et al. (2007). The HBV drug entecavir — Effects on HIV-1 replication
and resistance. N. Engl. J. Med. 356, 2614–2621. doi: 10.1056/NEJMoa
067710
McMurry, L. M., Oethinger, M., and Levy, S. B. (1998). Triclosan targets lipid
synthesis. Nature 394, 531–532. doi: 10.1038/28970
Michaelis, M., Doerr, H. W., and Cinatl, J. (2007). Valproic acid as anti-
cancer drug. Curr. Pharm. Des. 13, 3378–3393. doi: 10.2174/1381612077823
60519
Mobbs, B. G., and Johnson, I. E. (1991). Suppression of the growth of the
androgen-insensitive R3327 hi rat prostatic carcinoma by combined estrogen
and antiprogestin treatment. J. Steroid Biochem. Mol. Biol. 39, 713–722.
doi: 10.1016/0960-0760(91)90371-B
Niraula, S., Templeton, A. J., Vera-Badillo, F., Dodd, A., Nugent, Z., Joshua, A. M.,
et al. (2018). Duration of suppression of bone turnover following treatment with
zoledronic acid in men with metastatic castration-resistant prostate cancer.
Futur. Sci. OA 4:FSO253. doi: 10.4155/fsoa-2017
Noto, H., Goto, A., Tsujimoto, T., and Noda, M. (2012). Cancer risk in diabetic
patients treated with metformin: a systematic review and meta-analysis. PLoS
One 7:e33411. doi: 10.1371/journal.pone.0033411
Padhy, B. M., and Gupta, Y. K. (2011). Drug repositioning: re-investigating
existing drugs for new therapeutic indications. J. Postgrad. Med. 57, 153–160.
doi: 10.4103/0022-3859.81870
Pan, J. X., Ding, K., and Wang, C. Y. (2012). Niclosamide, an old antihelminthic
agent, demonstrates antitumor activity by blocking multiple signaling pathways
of cancer stem cells. Chin. J. Cancer 31, 178–184. doi: 10.5732/cjc.011.
10290
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., and Sukhatme, V. P. (2014).
The repurposing drugs in oncology (ReDO) project. ecancer 8:442. doi: 10.3332/
ecancer.2014.442
Pantziarka, P., Sukhatme, V., Bouche, G., Meheus, L., and Sukhatme, V. P. (2015).
Repurposing drugs in oncology (ReDO)—itraconazole as an anti-cancer agent.
Ecancermedicalscience 9:521. doi: 10.3332/ecancer.2015.521
Pantziarka, P., Sukhatme, V. V. P., Bouche, G., Melhuis, L., and Sukhatme, V. V. P.
(2016). Repurposing drugs in oncology (ReDO)—diclofenac as an anti-cancer
agent. Ecancermedicalscience 10:610. doi: 10.3332/ecancer.2016.610
Patel, M. I., Subbaramaiah, K., Du, B., Patel, M. I., Subbaramaiah, K., Du, B.,
et al. (2005). Celecoxib inhibits prostate cancer growth: evidence of a
cyclooxygenase-2-independent mechanism. Clin. Cancer. Res. 11, 1999–2007.
doi: 10.1158/1078-0432.CCR-04-1877
Pelletier, J., Bordeleau, M., Lindqvist, L., Francis, R., Sukarieh, R., and Tanaka, J.
(2007). Chemotherapeutic agents for inhibition of protein translation Vol.
WO2007/009264 A1, A61K 31/58 Edn.
Perry, C. M., and Figgitt, D. P. (2004). Zoledronic acid: a review of its use in
patients with advanced cancer. Drugs 64, 1197–1211. doi: 10.2165/00003495-
200464110-00004
Piao, S., and Amaravadi, R. K. (2016). Targeting the lysosome in cancer. Ann. N. Y.
Acad. Sci. 1371, 45–54. doi: 10.1111/nyas.12953
Platz, E. A., Yegnasubramanian, S., Liu, J. O., Chong, C. R., Shim, J. S., Kenfield,
S. A., et al. (2011). A novel two-stage, transdisciplinary study identifies digoxin
as a possible drug for prostate cancer treatment. Cancer Discov. 1, 68–77.
doi: 10.1158/2159-8274.CD-100020
Frontiers in Physiology | www.frontiersin.org 18 May 2018 | Volume 9 | Article 500
fphys-09-00500 May 12, 2018 Time: 14:44 # 19
Turanli et al. Repurposing Non-cancer Drugs for Prostate Cancer
Polascik, T. J., and Mouraviev, V. (2008). Zoledronic acid in the management of
metastatic bone disease. Ther. Clin. Risk Manage. 4, 261–268. doi: 10.2147/
TCRM.S2707
Ponder, B. (1997). Genetic testing for cancer risk. Science 278, 1050–1054.
doi: 10.1126/science.278.5340.1050
Preston, M. A., Riis, A. H., Ehrenstein, V., Breau, R. H., Batista, J. L., Olumi, A. F.,
et al. (2014). Metformin use and prostate cancer risk. Eur. Urol. 66, 1012–1020.
doi: 10.1016/j.eururo.2014.04.027
Qi, C., Li, B., Yang, Y. Y., Yang, Y. Y., Li, J. J., Zhou, Q., et al. (2016). Glipizide
suppresses prostate cancer progression in the TRAMP model by inhibiting
angiogenesis. Sci. Rep. 6:27819. doi: 10.1038/srep27819
Rebecca, V. W., and Amaravadi, R. K. (2016). Emerging strategies to effectively
target autophagy in cancer. Oncogene 35, 1–11. doi: 10.1038/onc.2015.99
Regen, F., Heuser, I., Herzog, I., and Hellmann-Regen, J. (2014). Striking growth-
inhibitory effects of minocycline on human prostate cancer cell lines. Urology
83, 509.e1–506.e1. doi: 10.1016/j.urology.2013.10.029
Roth, B. L., Sheﬄer, D. J., and Kroeze, W. K. (2004). Magic shotguns versus magic
bullets: selectively non-selective drugs for mood disorders and schizophrenia.
Nat. Rev. Drug Discov. 3, 353–359. doi: 10.1038/nrd1346
Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R.,
et al. (2013). Phase 2 study of pemetrexed and itraconazole as second-line
therapy for metastatic nonsquamous non-small-cell lung cancer. J. Thorac.
Oncol. 8, 619–623. doi: 10.1097/JTO.0b013e31828c3950
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L.,
et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in
patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer
Inst. 94, 1458–1468. doi: 10.1093/jnci/94.19.1458
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L.,
et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal
complications in patients with metastatic hormone-refractory prostate cancer.
J. Natl. Cancer Inst. 96, 879–882. doi: 10.1093/jnci/djh141
Sack, U., Walther, W., Scudiero, D., Selby, M., Kobelt, D., Lemm, M., et al. (2011).
Novel effect of antihelminthic niclosamide on s100a4-mediated metastatic
progression in colon cancer. J. Natl. Cancer Inst. 103, 1018–1036. doi: 10.1093/
jnci/djr190
Sadowski, M. C., Pouwer, R. H., Gunter, J. H., Lubik, A. A., Quinn, R. J., and
Nelson, C. C. (2014). The fatty acid synthase inhibitor triclosan: repurposing
an anti- microbial agent for targeting prostate cancer. Oncotarget 5, 9362–9381.
doi: 10.18632/oncotarget.2433
Safi, R., Nelson, E. R., Chitneni, S. K., Franz, K. J., George, D. J., Zalutsky, M. R.,
et al. (2014). Copper signaling axis as a target for prostate cancer therapeutics.
Cancer Res. 74, 5819–5831. doi: 10.1158/0008-5472.CAN-13-3527
Schemmel, K. E., Padiyara, R. S., and D’Souza, J. J. (2010). Aldose reductase
inhibitors in the treatment of diabetic peripheral neuropathy: a review.
J. Diabetes Complications 24, 354–360. doi: 10.1016/j.jdiacomp.2009.07.005
Schneider, H. C., and Klabunde, T. (2013). Understanding drugs and diseases by
systems biology? Bioorganic Med. Chem. Lett. 23, 1168–1176. doi: 10.1016/j.
bmcl.2012.12.031
Schweizer, M. T., Lin, J., Blackford, A., Bardia, A., King, S., Armstrong, A. J.,
et al. (2013). Pharmacodynamic study of disulfiram in men with non-metastatic
recurrent prostate cancer. Prostate Cancer Prostatic Dis. 16, 357–361. doi: 10.
1038/pcan.2013.28
Shaked, I., Oberhardt, M. A., Atias, N., Sharan, R., and Ruppin, E. (2016). Metabolic
network prediction of drug side effects. Cell Syst. 2, 209–213. doi: 10.1016/j.cels.
2016.03.001
Shamash, J., Powles, T., Sarker, S. J., Protheroe, A., Mithal, N., Mills, R., et al. (2011).
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone
and diethylstilbestrol in castration-resistant prostate cancer: immediate vs
deferred Diethylstilbestrol. Br. J. Cancer 104, 620–628. doi: 10.1038/bjc.
2011.7
Sharma, S., Symanowski, J., Wong, B., Dino, P., Manno, P., and Vogelzang, N.
(2008). A phase II clinical trial of oral valproic acid in patients with castration-
resistant prostate cancers using an intensive biomarker sampling strategy.
Transl. Oncol. 1, 141–147. doi: 10.1593/tlo.08136
Shawver, K., Schwartz, P., Mann, E., Chen, H., Tsai, J., Chu, L., et al. (1997).
Inhibition of platelet-derived growth factor-mediated signal transduction
and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-
carboxamide. Clin. Cancer Res. 3, 1167–1177
Shim, J. S., and Liu, J. O. (2014). Recent advances in drug repositioning for the
discovery of new anticancer drugs. Int. J. Biol. Sci. 10, 654–663. doi: 10.7150/
ijbs.9224
Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H. E. C., et al. (2010).
Effect of nitroxoline on angiogenesis and growth of human bladder cancer.
J. Natl. Cancer Inst. 102, 1855–1873. doi: 10.1093/jnci/djq457
Shoaie, S., Ghaffari, P., Kovatcheva-Datchary, P., Mardinoglu, A., Sen, P., Pujos-
Guillot, E., et al. (2015). Quantifying diet-induced metabolic changes of the
human gut microbiome. Cell Metab. 22, 320–331. doi: 10.1016/j.cmet.2015.
07.001
Siegel, R. L., Miller, K. D., and Jemal, A. (2018). Cancer statistics, 2018. CA Cancer
J. Clin. 68, 7–30. doi: 10.3322/caac.21442
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A.,
et al. (2011). Discovery and preclinical validation of drug indications using
compendia of public gene expression data. Sci. Transl. Med. 77:96ra77.
doi: 10.1126/scitranslmed.3001318
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., et al. (2017).
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
Nature 552, 194–199. doi: 10.1038/nature25016
Slingerland, M., Cerella, C., Guchelaar, H. J., Diederich, M., and Gelderblom, H.
(2013). Cardiac glycosides in cancer therapy: From preclinical investigations
towards clinical trials. Invest. New Drugs 31, 1087–1094. doi: 10.1007/s10637-
013-9984-1
Sosiè, I., Mirkoviæ, B., Arenz, K., Štefane, B., Kos, J., and Gobec, S. (2013).
Development of new cathepsin b inhibitors: combining bioisosteric
replacements and structure-based design to explore the structure-activity
relationships of nitroxoline derivatives. J. Med. Chem. 56, 521–533.
doi: 10.1021/jm301544x
Sun, P., Guo, J., Winnenburg, R., and Baumbach, J. (2017). Drug repurposing by
integrated literature mining and drug–gene–disease triangulation. Drug Discov.
Today 22, 615–619. doi: 10.1016/j.drudis.2016.10.008
Sussman, G. L., Mason, J., Compton, D., Stewart, J., and Ricard, N. (1999).
The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and
in combination, in seasonal allergic rhinitis. J. Allergy Clin. Immunol. 104,
100–106. doi: 10.1016/S0091-6749(99)70120-X
Tammali, R., Srivastava, S. K., and Ramana, K. V. (2011). Targeting aldose
reductase for the treatment of cancer. Curr. Cancer Drug Targets 11, 560–571.
doi: 10.2174/156800911795655958
Tan, N., Klein, E. A., Li, J., Moussa, A. S., and Jones, J. S. (2011). Statin use and risk
of prostate cancer in a population of men who underwent biopsy. J. Urol. 186,
86–90. doi: 10.1016/j.juro.2011.03.004
Tan, X., Liu, P., Huang, Y., Zhou, L., Yang, Y., Wang, H., et al. (2016).
Phosphoproteome analysis of invasion and metastasis-related factors in
pancreatic cancer cells. PLoS One 11:e0152280. doi: 10.1371/journal.pone.
0152280
Taplin, M. E., Manola, J., Oh, W. K., Kantoff, P. W., Bubley, G. J., Smith, M.,
et al. (2008). A phase II study of mifepristone (RU-486) in castration-resistant
prostate cancer, with a correlative assessment of androgen-related hormones.
BJU Int. 101, 1084–1089. doi: 10.1111/j.1464-410X.2008.07509.x
Thiele, I., Clancy, C. M., Heinken, A., and Fleming, R. M. T. (2017). Quantitative
systems pharmacology and the personalized drug–microbiota–diet axis. Curr.
Opin. Syst. Biol. 4, 43–52. doi: 10.1016/j.coisb.2017.06.001
Tieszen, C. R., Goyeneche, A. A., Brandhagen, B. N., Ortbahn, C. T., and
Telleria, C. M. (2011). Antiprogestin mifepristone inhibits the growth of
cancer cells of reproductive and non-reproductive origin regardless of
progesterone receptor expression. BMC Cancer 11:207. doi: 10.1186/1471-2407-
11-207
Tran, L. N. K., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L.,
Ormsby, R. J., et al. (2017). The combination of metformin and valproic acid
induces synergistic apoptosis in the presence of p53 and androgen signaling
in prostate cancer. Mol. Cancer Ther. 16, 2689–2700. doi: 10.1158/1535-7163.
MCT-17-0074
Tsubamoto, H., Ueda, T., Inoue, K., Sakata, K., Shibahara, H., and Sonoda, T.
(2017). Repurposing itraconazole as an anticancer agent (Review). Oncol. Lett.
14, 1240–1246. doi: 10.3892/ol.2017.6325
Turanli, B., Gulfidan, G., and Arga, K. Y. (2017). Transcriptomic-guided drug
repositioning supported by a new bioinformatics search tool: geneXpharma.
OMICS 21, 584–591. doi: 10.1089/omi.2017.0127
Frontiers in Physiology | www.frontiersin.org 19 May 2018 | Volume 9 | Article 500
fphys-09-00500 May 12, 2018 Time: 14:44 # 20
Turanli et al. Repurposing Non-cancer Drugs for Prostate Cancer
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., et al. (2017).
A pathology atlas of the human cancer transcriptome. Science 357:eaan2507.
doi: 10.1126/science.aan2507
Ummanni, R., Mundt, F., Pospisil, H., Venz, S., Scharf, C., Barett, C., et al. (2011).
Identification of clinically relevant protein targets in prostate cancer with 2D-
DIGE coupled mass spectrometry and systems biology network platform. PLoS
One 6:e16833. doi: 10.1371/journal.pone.0016833
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I.,
et al. (2017). Design of efficient computational workflows for in silico drug
repurposing. Drug Discov. Today 22, 210–222. doi: 10.1016/j.drudis.2016.
09.019
Vidal, A. C., Howard, L. E., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L.,
and Freedland, S. J. (2015). Aspirin, NSAIDs, and risk of prostate cancer: results
from the REDUCE study. Clin. Cancer Res. 21, 756–762. doi: 10.1158/1078-
0432.CCR-14-2235
Wang, M., Shim, J. S., Li, R. J., Dang, Y., He, Q., Das, M., et al. (2014). Identification
of an old antibiotic clofoctol as a novel activator of unfolded protein response
pathways and an inhibitor of prostate cancer. Br. J. Pharmacol. 171, 4478–4489.
doi: 10.1111/bph.12800
Wang, Y.-C., Chao, T.-K., Chang, C.-C., Yo, Y.-T., Yu, M.-H., and Lai, H.-C.
(2013). Drug screening identifies niclosamide as an inhibitor of breast cancer
stem-like cells. PLoS One 8:e74538. doi: 10.1371/journal.pone.0074538
Whitburn, J., Edwards, C. M., and Sooriakumaran, P. (2017). Metformin and
prostate cancer: a new role for an old drug. Curr. Urol. Rep. 18:46. doi: 10.1007/
s11934-017-0693-8
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., and Barbieri, F. (2016).
Drug-repositioning opportunities for cancer therapy: novel molecular targets
for known compounds. Drug Discov. Today 21, 190–199. doi: 10.1016/j.drudis.
2015.09.017
Xia, Q., Sung, J., Chowdhury, W., Chen, C.-L., Höti, N., Shabbeer, S., et al. (2006).
Chronic administration of valproic acid inhibits prostate cancer cell growth
in vitro and in vivo. Cancer Res. 66, 7237–7244. doi: 10.1158/0008-5472.CAN-
05-0487
Xia, W., Lan, X., Lv, J., Ma, J., Chen, W., Gao, L., et al. (2016). Valproic acid (VPA)
suppresses the expression of SMAD4 in prostate carcinoma by up-regulating
miR-34a. Int. J. Clin. Exp. Med. 9, 20466–20473.
Xu, T., Brandmaier, S., Messias, A. C., Herder, C., Draisma, H. H. M., Demirkan, A.,
et al. (2015). Effects of metformin on metabolite profiles and LDL cholesterol in
patients with type 2 diabetes. Diabetes Care 38, 1858–1867. doi: 10.2337/dc15-
0658
Xu, X., Shen, J., Mall, J. W., Myers, J. A., Huang, W., Blinder, L., et al. (1999). In vitro
and in vivo antitumor activity of a novel immunomodulatory drug. Leflunomide
58, 1405–1413. doi: 10.1016/S0006-2952(99)00228-2
Xu, Y., Fang, F., Sun, Y., St Clair, D. K., and St Clair, W. H. (2010). RelB-dependent
differential radiosensitization effect of STI571 on prostate cancer cells. Mol.
Cancer Ther. 9, 803–812. doi: 10.1158/1535-7163.MCT-09-1001
Yizhak, K., Chaneton, B., Gottlieb, E., and Ruppin, E. (2015). Modeling cancer
metabolism on a genome scale. Mol. Syst. Biol. 11, 817–817. doi: 10.15252/msb.
20145307
Yizhak, K., Gabay, O., Cohen, H., and Ruppin, E. (2013). Model-based
identification of drug targets that revert disrupted metabolism and its
application to ageing. Nat. Commun. 4:2632. doi: 10.1038/ncomms3632
Yo, Y.-T., Lin, Y.-W., Wang, Y.-C., Balch, C., Huang, R.-L., Chan, M. W. Y., et al.
(2012). Growth inhibition of ovarian tumor-initiating cells by Niclosamide.
Mol. Cancer Ther. 11, 1703–1712. doi: 10.1158/1535-7163.MCT-12-0002
Yoshimura, R., Sano, H., Masuda, C., Kawamura, M., Tsubouchi, Y., Chargui, J.,
et al. (2000). Expression of cyclooxygenase-2 in prostate carcinoma. Cancer
89, 589–596. doi: 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.
CO;2-C
Yu, S., Yang, X., Zhu, Y., Xie, F., Lu, Y., Yu, T., et al. (2015). Systems pharmacology
of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive
analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep.
5:7830. doi: 10.1038/srep07830
Zhang, C., and Hua, Q. (2016). Applications of genome-scale metabolic models in
biotechnology and systems medicine. Front. Physiol. 6:413. doi: 10.3389/fphys.
2015.00413
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., et al. (2008).
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block
tumor growth. Proc. Natl. Acad. Sci. U.S.A. 105, 19579–19586. doi: 10.1073/
pnas.0809763105
Zhang, Q., Wang, S., Yang, D., Pan, K., Li, L., and Yuan, S. (2016). Preclinical
pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug
repurposing. Oncol. Lett. 11, 3265–3272. doi: 10.3892/ol.2016.4380
Zhang, W., Edwards, A., Fan, W., Flemington, E. K., and Zhang, K. (2012).
MiRNA-mRNA correlation-network modules in human prostate cancer and
the differences between primary and metastatic tumor subtypes. PLoS One
7:e40130. doi: 10.1371/journal.pone.0040130
Zhu, C. (2013). “Aldose reductase inhibitors as potential therapeutic drugs of
diabetic complications,” in Diabetes Mellitus - Insights and Perspectives, ed. O.
Oguntibeju (Rijeka: InTech).
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Turanli, Grøtli, Boren, Nielsen, Uhlen, Arga and Mardinoglu.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Physiology | www.frontiersin.org 20 May 2018 | Volume 9 | Article 500
